GB2596849A - Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual - Google Patents
Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual Download PDFInfo
- Publication number
- GB2596849A GB2596849A GB2010600.1A GB202010600A GB2596849A GB 2596849 A GB2596849 A GB 2596849A GB 202010600 A GB202010600 A GB 202010600A GB 2596849 A GB2596849 A GB 2596849A
- Authority
- GB
- United Kingdom
- Prior art keywords
- amount
- vitamin
- formulation
- composition
- composition further
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 289
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 48
- 201000011510 cancer Diseases 0.000 title claims abstract description 41
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title description 85
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title description 85
- 235000015872 dietary supplement Nutrition 0.000 title description 12
- 230000004770 neurodegeneration Effects 0.000 title description 12
- 208000001528 Coronaviridae Infections Diseases 0.000 title description 6
- 230000003612 virological effect Effects 0.000 title description 5
- 238000009472 formulation Methods 0.000 claims abstract description 81
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 77
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 58
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 58
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 45
- 210000000130 stem cell Anatomy 0.000 claims abstract description 45
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 43
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 42
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 41
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 41
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 39
- 229930003571 Vitamin B5 Natural products 0.000 claims abstract description 36
- 235000009492 vitamin B5 Nutrition 0.000 claims abstract description 36
- 239000011675 vitamin B5 Substances 0.000 claims abstract description 36
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 33
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 33
- 235000019100 piperine Nutrition 0.000 claims abstract description 32
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims abstract description 32
- 229940075559 piperine Drugs 0.000 claims abstract description 32
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960003495 thiamine Drugs 0.000 claims abstract description 32
- 241000711573 Coronaviridae Species 0.000 claims abstract description 29
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 29
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 29
- 235000016804 zinc Nutrition 0.000 claims abstract description 29
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 29
- 239000011701 zinc Substances 0.000 claims abstract description 29
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 28
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 28
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 28
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 27
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 27
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 26
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 26
- 208000015181 infectious disease Diseases 0.000 claims abstract description 25
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 24
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 24
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 24
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 23
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 claims abstract description 22
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 claims abstract description 22
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 21
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 21
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000005875 quercetin Nutrition 0.000 claims abstract description 21
- 229960001285 quercetin Drugs 0.000 claims abstract description 21
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 20
- 229930003761 Vitamin B9 Natural products 0.000 claims abstract description 20
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 20
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 20
- 235000019159 vitamin B9 Nutrition 0.000 claims abstract description 20
- 239000011727 vitamin B9 Substances 0.000 claims abstract description 20
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960002477 riboflavin Drugs 0.000 claims abstract description 19
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 18
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 18
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000003925 brain function Effects 0.000 claims abstract description 17
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 17
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims abstract description 16
- 230000002113 chemopreventative effect Effects 0.000 claims abstract description 16
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims abstract description 16
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims abstract description 16
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 15
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims abstract description 15
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims abstract description 14
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims abstract description 14
- 229920002079 Ellagic acid Polymers 0.000 claims abstract description 14
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 14
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 14
- 229960002852 ellagic acid Drugs 0.000 claims abstract description 14
- 235000004132 ellagic acid Nutrition 0.000 claims abstract description 14
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 14
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 14
- QGDOQULISIQFHQ-UHFFFAOYSA-N 1,3,7,9-tetramethyluric acid Chemical compound CN1C(=O)N(C)C(=O)C2=C1N(C)C(=O)N2C QGDOQULISIQFHQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 12
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 12
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 12
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 12
- 229940114496 olive leaf extract Drugs 0.000 claims abstract description 12
- 229940109529 pomegranate extract Drugs 0.000 claims abstract description 12
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 11
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 claims abstract description 11
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 claims abstract description 11
- 229930003756 Vitamin B7 Natural products 0.000 claims abstract description 11
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 11
- 229940094952 green tea extract Drugs 0.000 claims abstract description 11
- 235000003248 hydroxytyrosol Nutrition 0.000 claims abstract description 11
- 229940095066 hydroxytyrosol Drugs 0.000 claims abstract description 11
- 235000011576 oleuropein Nutrition 0.000 claims abstract description 11
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 claims abstract description 11
- 235000011912 vitamin B7 Nutrition 0.000 claims abstract description 11
- 239000011735 vitamin B7 Substances 0.000 claims abstract description 11
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 10
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 9
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 9
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 9
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 8
- 230000006563 epigenetic aging Effects 0.000 claims abstract description 8
- 229940069765 bean extract Drugs 0.000 claims abstract description 7
- 239000008513 turmeric extract Substances 0.000 claims abstract description 7
- 229940052016 turmeric extract Drugs 0.000 claims abstract description 7
- 235000020240 turmeric extract Nutrition 0.000 claims abstract description 7
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 26
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 25
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 20
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 20
- -1 glucosamine salt Chemical class 0.000 claims description 20
- 229910052749 magnesium Inorganic materials 0.000 claims description 20
- 239000011777 magnesium Substances 0.000 claims description 20
- 229940091250 magnesium supplement Drugs 0.000 claims description 20
- 229960001231 choline Drugs 0.000 claims description 19
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 19
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 19
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 18
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 18
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 17
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 17
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 17
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 15
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 15
- 235000021283 resveratrol Nutrition 0.000 claims description 15
- 229940016667 resveratrol Drugs 0.000 claims description 15
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 14
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 13
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 13
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 12
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 11
- 229960003080 taurine Drugs 0.000 claims description 11
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 10
- 229960003624 creatine Drugs 0.000 claims description 10
- 239000006046 creatine Substances 0.000 claims description 10
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 10
- 235000020957 pantothenol Nutrition 0.000 claims description 10
- 239000011619 pantothenol Substances 0.000 claims description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 9
- 229960005305 adenosine Drugs 0.000 claims description 9
- 229950006238 nadide Drugs 0.000 claims description 9
- 229940055726 pantothenic acid Drugs 0.000 claims description 9
- 235000019161 pantothenic acid Nutrition 0.000 claims description 9
- 239000011713 pantothenic acid Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 235000021467 vitamin B7(Biotin) Nutrition 0.000 claims description 9
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims description 8
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 8
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 239000002509 fulvic acid Substances 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- ZVQXCXPGLSBNCX-UHFFFAOYSA-N methylliberine Chemical compound O=C1N(C)C(OC)=NC2=C1N(C)C(=O)N2C ZVQXCXPGLSBNCX-UHFFFAOYSA-N 0.000 claims description 8
- 239000000693 micelle Substances 0.000 claims description 8
- 235000008975 pantethine Nutrition 0.000 claims description 8
- 239000011581 pantethine Substances 0.000 claims description 8
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims description 8
- 229960000903 pantethine Drugs 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 235000019157 thiamine Nutrition 0.000 claims description 8
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 8
- 239000011721 thiamine Substances 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 8
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 7
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 claims description 7
- 229960002873 benfotiamine Drugs 0.000 claims description 7
- 229960003237 betaine Drugs 0.000 claims description 7
- YVBGRQLITPHVOP-UHFFFAOYSA-L disodium;[hydroxy-[hydroxy(oxido)phosphoryl]oxyphosphoryl] hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)(=O)OP(O)([O-])=O YVBGRQLITPHVOP-UHFFFAOYSA-L 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 235000007672 methylcobalamin Nutrition 0.000 claims description 7
- 239000011585 methylcobalamin Substances 0.000 claims description 7
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 claims description 7
- 235000010755 mineral Nutrition 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 claims description 6
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 229960004874 choline bitartrate Drugs 0.000 claims description 6
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 claims description 6
- 229960001284 citicoline Drugs 0.000 claims description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 6
- 108700003601 dimethylglycine Proteins 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 claims description 6
- 235000008160 pyridoxine Nutrition 0.000 claims description 6
- 239000011677 pyridoxine Substances 0.000 claims description 6
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 claims description 6
- 229960003211 sulbutiamine Drugs 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 235000004866 D-panthenol Nutrition 0.000 claims description 5
- 239000011703 D-panthenol Substances 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 229950010582 betaine anhydrous Drugs 0.000 claims description 5
- QJWNYSRCYOCRGE-UHFFFAOYSA-O carboxymethyl(trimethyl)azanium;nitrate Chemical compound [O-][N+]([O-])=O.C[N+](C)(C)CC(O)=O QJWNYSRCYOCRGE-UHFFFAOYSA-O 0.000 claims description 5
- 229960003949 dexpanthenol Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 229940101267 panthenol Drugs 0.000 claims description 5
- 229960003581 pyridoxal Drugs 0.000 claims description 5
- 235000008164 pyridoxal Nutrition 0.000 claims description 5
- 239000011674 pyridoxal Substances 0.000 claims description 5
- WHOMFKWHIQZTHY-UHFFFAOYSA-L pyridoxine 5'-phosphate(2-) Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(CO)=C1O WHOMFKWHIQZTHY-UHFFFAOYSA-L 0.000 claims description 5
- 229940032991 zinc picolinate Drugs 0.000 claims description 5
- NHVUUBRKFZWXRN-UHFFFAOYSA-L zinc;pyridine-2-carboxylate Chemical compound C=1C=CC=NC=1C(=O)O[Zn]OC(=O)C1=CC=CC=N1 NHVUUBRKFZWXRN-UHFFFAOYSA-L 0.000 claims description 5
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 claims description 4
- 235000007319 Avena orientalis Nutrition 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 240000005979 Hordeum vulgare Species 0.000 claims description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 4
- 229930003270 Vitamin B Natural products 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 239000011578 levomefolic acid Substances 0.000 claims description 4
- 229960003208 levomefolic acid Drugs 0.000 claims description 4
- 229940056905 magnesium l-threonate Drugs 0.000 claims description 4
- YVJOHOWNFPQSPP-BALCVSAKSA-L magnesium;(2r,3s)-2,3,4-trihydroxybutanoate Chemical compound [Mg+2].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O YVJOHOWNFPQSPP-BALCVSAKSA-L 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 235000019156 vitamin B Nutrition 0.000 claims description 4
- 239000011720 vitamin B Substances 0.000 claims description 4
- 241000209763 Avena sativa Species 0.000 claims description 3
- 235000007558 Avena sp Nutrition 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims description 3
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 3
- 239000011666 cyanocobalamin Substances 0.000 claims description 3
- 229960002104 cyanocobalamin Drugs 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- 235000004867 hydroxocobalamin Nutrition 0.000 claims description 3
- 239000011704 hydroxocobalamin Substances 0.000 claims description 3
- 229960001103 hydroxocobalamin Drugs 0.000 claims description 3
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims description 3
- 235000007635 levomefolic acid Nutrition 0.000 claims description 3
- 229960001983 magnesium aspartate Drugs 0.000 claims description 3
- 229960005336 magnesium citrate Drugs 0.000 claims description 3
- 239000004337 magnesium citrate Substances 0.000 claims description 3
- 235000002538 magnesium citrate Nutrition 0.000 claims description 3
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 claims description 3
- 239000000626 magnesium lactate Substances 0.000 claims description 3
- 229960004658 magnesium lactate Drugs 0.000 claims description 3
- 235000015229 magnesium lactate Nutrition 0.000 claims description 3
- QWLHYYKDLOVBNV-UHFFFAOYSA-L magnesium orotate Chemical compound [Mg+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QWLHYYKDLOVBNV-UHFFFAOYSA-L 0.000 claims description 3
- 229960000407 magnesium orotate Drugs 0.000 claims description 3
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 claims description 3
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 claims description 3
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims description 3
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 239000011670 zinc gluconate Substances 0.000 claims description 3
- 235000011478 zinc gluconate Nutrition 0.000 claims description 3
- 229960000306 zinc gluconate Drugs 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 229960001296 zinc oxide Drugs 0.000 claims description 3
- 235000014692 zinc oxide Nutrition 0.000 claims description 3
- MBBREGJRSROLGD-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NC(=N)N(C)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MBBREGJRSROLGD-UHFFFAOYSA-N 0.000 claims description 2
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 claims description 2
- DGOAYHVIVJYHKU-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrochloride Chemical compound Cl.NC(=N)N(C)CC(O)=O DGOAYHVIVJYHKU-UHFFFAOYSA-N 0.000 claims description 2
- MBSCHHMCRIMBDZ-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;nitric acid Chemical compound O[N+]([O-])=O.NC(=N)N(C)CC(O)=O MBSCHHMCRIMBDZ-UHFFFAOYSA-N 0.000 claims description 2
- SVJMLYUFVDMUHP-UHFFFAOYSA-N Niguldipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 SVJMLYUFVDMUHP-UHFFFAOYSA-N 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims description 2
- 229960004826 creatine monohydrate Drugs 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims description 2
- 235000020744 piper nigrum extract Nutrition 0.000 claims description 2
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 abstract description 22
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 230000008901 benefit Effects 0.000 description 45
- 230000000694 effects Effects 0.000 description 35
- 206010057244 Post viral fatigue syndrome Diseases 0.000 description 33
- 208000025721 COVID-19 Diseases 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 30
- 230000001093 anti-cancer Effects 0.000 description 29
- 230000000840 anti-viral effect Effects 0.000 description 28
- 230000007423 decrease Effects 0.000 description 28
- 230000036541 health Effects 0.000 description 26
- 210000000987 immune system Anatomy 0.000 description 26
- 230000004898 mitochondrial function Effects 0.000 description 26
- 230000003078 antioxidant effect Effects 0.000 description 24
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 24
- 230000006870 function Effects 0.000 description 24
- 206010061218 Inflammation Diseases 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 22
- 230000004054 inflammatory process Effects 0.000 description 21
- 210000004556 brain Anatomy 0.000 description 20
- 230000003110 anti-inflammatory effect Effects 0.000 description 18
- 239000003963 antioxidant agent Substances 0.000 description 18
- 230000035755 proliferation Effects 0.000 description 18
- 235000006708 antioxidants Nutrition 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 230000008437 mitochondrial biogenesis Effects 0.000 description 17
- 230000036542 oxidative stress Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 210000002345 respiratory system Anatomy 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 230000003389 potentiating effect Effects 0.000 description 14
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 13
- 230000006907 apoptotic process Effects 0.000 description 12
- 235000012754 curcumin Nutrition 0.000 description 12
- 239000004148 curcumin Substances 0.000 description 12
- 229940109262 curcumin Drugs 0.000 description 12
- 206010052015 cytokine release syndrome Diseases 0.000 description 12
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 12
- 230000002708 enhancing effect Effects 0.000 description 12
- 239000002955 immunomodulating agent Substances 0.000 description 12
- 230000002584 immunomodulator Effects 0.000 description 12
- 229940121354 immunomodulator Drugs 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 230000004065 mitochondrial dysfunction Effects 0.000 description 12
- 230000036651 mood Effects 0.000 description 12
- 206010050685 Cytokine storm Diseases 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 11
- 230000032683 aging Effects 0.000 description 11
- 230000024245 cell differentiation Effects 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 210000003470 mitochondria Anatomy 0.000 description 11
- 210000001178 neural stem cell Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000000241 respiratory effect Effects 0.000 description 11
- 108091035539 telomere Proteins 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 230000004064 dysfunction Effects 0.000 description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 10
- 230000015654 memory Effects 0.000 description 10
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 102000055501 telomere Human genes 0.000 description 9
- 210000003411 telomere Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000002407 ATP formation Effects 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 230000000324 neuroprotective effect Effects 0.000 description 8
- 239000013589 supplement Substances 0.000 description 8
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 7
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 7
- 229960003321 baicalin Drugs 0.000 description 7
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 7
- 230000036995 brain health Effects 0.000 description 7
- 230000003915 cell function Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000003920 cognitive function Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 208000019622 heart disease Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 6
- 206010057190 Respiratory tract infections Diseases 0.000 description 6
- 206010040047 Sepsis Diseases 0.000 description 6
- 108010017842 Telomerase Proteins 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 206010069351 acute lung injury Diseases 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000008436 biogenesis Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000005189 cardiac health Effects 0.000 description 6
- 230000003293 cardioprotective effect Effects 0.000 description 6
- 208000037976 chronic inflammation Diseases 0.000 description 6
- 230000019771 cognition Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000035558 fertility Effects 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 230000015788 innate immune response Effects 0.000 description 6
- 230000011987 methylation Effects 0.000 description 6
- 238000007069 methylation reaction Methods 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241001678559 COVID-19 virus Species 0.000 description 5
- 108010024636 Glutathione Proteins 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 102000011990 Sirtuin Human genes 0.000 description 5
- 108050002485 Sirtuin Proteins 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 230000002715 bioenergetic effect Effects 0.000 description 5
- 230000006020 chronic inflammation Effects 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000003969 glutathione Nutrition 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000004766 neurogenesis Effects 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 235000021436 nutraceutical agent Nutrition 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 235000019192 riboflavin Nutrition 0.000 description 5
- 239000002151 riboflavin Substances 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000004906 unfolded protein response Effects 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 230000007067 DNA methylation Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000009429 Ginkgo biloba extract Substances 0.000 description 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 241000315672 SARS coronavirus Species 0.000 description 4
- 241000533293 Sesbania emerus Species 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000003930 cognitive ability Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000004966 intestinal stem cell Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000001777 nootropic effect Effects 0.000 description 4
- 239000002417 nutraceutical Substances 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 108010087806 Carnosine Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000003502 anti-nociceptive effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 3
- 230000006369 cell cycle progression Effects 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 239000012829 chemotherapy agent Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000003492 excitotoxic effect Effects 0.000 description 3
- 231100000063 excitotoxicity Toxicity 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 229940068052 ginkgo biloba extract Drugs 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002443 hepatoprotective effect Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 239000002664 nootropic agent Substances 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 235000017807 phytochemicals Nutrition 0.000 description 3
- 229930000223 plant secondary metabolite Natural products 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 2
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 208000037487 Endotoxemia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 2
- 241000723754 Flock house virus Species 0.000 description 2
- 102100035233 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 241000712003 Human respirovirus 3 Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010038687 Respiratory distress Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108010041191 Sirtuin 1 Proteins 0.000 description 2
- 102000000478 Sirtuin 3 Human genes 0.000 description 2
- 108010041218 Sirtuin 3 Proteins 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000037147 athletic performance Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000001625 cardiomyogenic effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 230000037411 cognitive enhancing Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 230000037080 exercise endurance Effects 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002555 ionophore Substances 0.000 description 2
- 230000000236 ionophoric effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 231100000516 lung damage Toxicity 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000006677 mitochondrial metabolism Effects 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000000933 neural crest Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 210000000717 sertoli cell Anatomy 0.000 description 2
- 230000035911 sexual health Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 230000023895 stem cell maintenance Effects 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- GJTJQSPLLQWKMB-SECBINFHSA-N (3R)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]pentanoate Chemical compound C(C)(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O GJTJQSPLLQWKMB-SECBINFHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- YBJHBAHKTGYVGT-OOZYFLPDSA-N 5-[(3as,4r,6ar)-2-oxohexahydro-1h-thieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-OOZYFLPDSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 208000004481 Choline Deficiency Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- FIKLMMHLPVXWJN-WRWORJQWSA-N Elenolic acid Chemical compound COC(=O)C1=CO[C@@H](O)C(=CC)[C@@H]1CC(O)=O FIKLMMHLPVXWJN-WRWORJQWSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-N FADH2 Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-N 0.000 description 1
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 241000390476 Ganoderma lingzhi Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- KGPYBLOBHQLIET-OAHLLOKOSA-N KOM70144 Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)C(=O)C1=CC(NC(C)=O)=CC=C1C KGPYBLOBHQLIET-OAHLLOKOSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000003043 Persistent hyperplastic primary vitreous Diseases 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 108091005532 SARS-CoV-2 main proteases Proteins 0.000 description 1
- 108700038444 SARS-CoV-2 papain-like protease Proteins 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 101150109526 Sirt6 gene Proteins 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000005428 Thiamine Deficiency Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 241001489129 Xerocomus badius Species 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000021752 choline deficiency disease Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000004633 cognitive health Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 229940090568 combinations of vitamin Drugs 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229940095100 fulvic acid Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000004409 healthy vision Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- YVJOHOWNFPQSPP-PZXRSRGQSA-L magnesium;(2s,3r)-2,3,4-trihydroxybutanoate Chemical compound [Mg+2].OC[C@@H](O)[C@H](O)C([O-])=O.OC[C@@H](O)[C@H](O)C([O-])=O YVJOHOWNFPQSPP-PZXRSRGQSA-L 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000022886 mitochondrial translation Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000007126 proinflammatory cytokine response Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A chemo-preventative and cytotoxic formulation for treating coronavirus and other infections, cancer, PVFS/ME/CFS, fibromyalgia, improving immune, mitochondrial, stem cell and brain function, and reversing epigenetic aging, in an individual, comprising NMN, NAD, PQQ, CoQ10, piperine, vitamin B7, vitamin B9, and vitamin B12. Further disclosed is a chemo-preventative and cytotoxic formulation for treating coronavirus and other infections, cancer, PVFS/ME/CFS, fibromyalgia, improving immune, mitochondrial, stem cell and brain function, and reversing epigenetic aging, in an individual, comprising Resveratol, Pterostilbene, Quercetin, Baikal Skullcap, L-Theanine, Curcuminoids (Turmeric Extract), Lion’s Mane Mushrooms, vitamin B1, vitamin B2, vitamin B5, vitamin B6, Piperine and Zinc Complex. Further disclosed is chemo-preventative and cytotoxic formulation for treating coronavirus and other infections, cancer, PVFS/ME/CFS, fibromyalgia, improving immune, mitochondrial, stem cell and brain function, and reversing epigenetic aging, in an individual, comprising Alpha Lipoic Acid (ALA), Acetyl-L-Carnitine (ALCAR), N-Acetyl Cysteine (NAC), Ginkgo Biloba, Beta Glucans, Epigallocatechin 3-Gallate (EGCG), Green Tea Extract, Pomegranate Extract (incl. Ellagic Acid), Olive Leaf Extract (incl. Oleuropein and Hydroxytyrosol), Green Coffee Bean Extract (incl. Chlorogenic Acids), Theacrine and piperine.
Description
NUTRITIONAL SUPPLEMENT COMPOSITION FOR TREATING CORONAVIRUS
INFECTIONS, CANCER, ME, POST VIRAL & CHRONIC FATIGUE SYNDROME &
NEURODEGENERATION IN AN INDIVIDUAL
BACKGROUND OF THE INVENTION
A. Technical field
[0001] The present invention relates to a composition for treating covid-19 (coronavirus infections), diabetes, respiratory tract infections and acute lung injury, post viral fatigue syndrome (PVFS) and chronic fatigue syndrome (CFS) / myalgic encephalomyelitis (ME), fibromyalgia, heart diseases, inflammation, cancers, and cytokine storms and also improving immune system, stem cells, mitochondrial function, brain heath, slowing and reversing epigenetic ageing in an individual by using an active combination of substances selected from the group consisting of phytochemicals and bio-tech nutraceuticals and thereof
B. Description of related art
[0002] Human brain changes with age and mental function changes along with it. Mental decline is common, and it's one of the most feared consequences of aging but cognitive impairment is not inevitable. Many attempts have been made to develop treatments and formulations to extend and improve the brain health and the quality of life. Numerous approaches are known in the art to enhance cognitive performance in normal individuals. More recently, certain nutraceutical agents have claimed cognitive enhancing effects. In other examples, various supplements and formulations comprising a multiplicity of allegedly active ingredients are marketed as nootropics, or cognitive enhancing agents to enhance brain function, mood and cognitive ability in normal individuals. However, currently most available nutraceutical supplements and formulations may therefore have no significant in the brain health of relatively wide age range and also fail to provide optimal health benefits [0003] One such a prior art device is described in US20160038552 assigned to Dale E. Bredesen et.al, entitled "Improved cognitive supplements" discloses nootropics sublingual power supplements are used to improve the cognitive functions such as learning, memory, concentration, focus, attention, and mood. The supplements comprising vitamin B9 (folate) can dose 0.4 mg to about 10 mg, vitamin B9 (methylcobalamin) can dose 2.5 mg to about 10 mg, L-Alpha Glycerylphosphorylcholine (Alpha GPC) can dose 100 mg to about 2000 mg, Magnesium Threonate can dose 200 mg to about 800 mg, L-theanine, ginkgo biloba, acetyl L-camitine (ALCAR), sweeteners and flavorings are added. The Alpha GPC is the one of the brain's most important neurotransmitters associated with heightened states of attention, improved memory and learning. ALCAR enhances cognitive ability because it increases the production and release of acetylcholine in the brain. Studies have shown that ALCAR supplementation enhances mood, memory, visuo-spatial capacity, and vocabulary recall. The Ginkgo leaf extract has been reported to have neuroprotective, anticancer, cardioprotective, stress alleviating, and memory enhancing effects and possible effects on tinnitus, geriatric complaints, and psychiatric disorders.
100041 Another prior art W02019074617 assigned to Kilman Clarke lewis, discloses about dietary supplement comprises combinations of vitamins and substances that are naturally endogenous to the brain, are known to decline with age, injury and disease and are essential for membrane structure, mitochondria] respiration and stem cell differentiation. The powder is administered by means of sublingual. The composition comprising pyrroloquinoline quinone (PQQ) can dosage in the range 1 mg to about 200mg, Folic acid can dose in the range mg to 200mg, Vitamin B12 can dose in the range mg to 200mg, alpha lipoic acid and acetyl-L-carnitine. However, the existing nootropics sublingual power supplements and dietary supplements are not effective in improving brain's health and cognitive functions such as learning, memory, concentration, focus, attention, and mood.
100051 Accordingly, there is a need for a nutritional supplement composition or formulation in the form of capsules or a tablet or liquid, liposomal, micelle, phospholipids or topical form, soft gels, drinks, powder, medical food, intravenous and an oral composition for improving cognition or rejuvenating ability and brain function and also treating covid-19 (coronavirus infections) of an individual using an active combination of substance selected from the group consisting of phytochemicals and bio-tech nutraceuticals and thereof Further, there is also a need for a nutritional supplement to provide one or more benefits include, but not limited to, promote immune system health, healthy nerve and neural stem cell function, treats post viral fatigue / chronic fatigue syndrome / myalgic encephalomyeltis and also decreases inflammation, free radicals, and provides anti-aging benefits.
SUMMARY OF THE INVENTION
100061 According to an embodiment, the present invention discloses a chemo-preventative and cytotoxic formulation or composition is effective in treating coronavirus and other infections, cancer, PVLS/M1E/CES, fibromyalgia, improving immune, mitochondrial, stem cell and brain function, and reversing epigenetic aging, in an individual.
100071 In one embodiment, the chemo-preventative and cytotoxic formulation comprises Nicotinamide Mononucleotide (NMN), Nicotinamide Adenine Dinucleotide (NAD), Pyrroquinoline Quinone (PQQ), Coenzyme Q10 (CoQ10), Piperine (black pepper extract), vitamin B7 (Biotin), vitamin B9, and vitamin B12.
100081 In one embodiment, the vitamin B9 is selected from at least any one of but not limited to, Folic Acid, L-5-Methyl tetrahydrofolate-Ca (calcium & non calcium salt of MethylFolate) and (6S)-5-methyl tetrahydrofol ate (glucosamine salt) In one embodiment, the vitamin B12 is selected from at least any one of, but not limited to Methylcobalamin, Adenocobalamin, Hydroxocobalamin, and Cyanocobalamin.
100091 In one embodiment, the composition further comprises vitamin B1. In one embodiment, the composition further comprises vitamin B1 in the amount from about 10 mg to 300 mg. In one embodiment, the composition further comprises vitamin B1 in the amount of about 100 mg. In one embodiment, the vitamin B1 is selected from at least any one of, but not limited to, Benfoti amine, Thiamine and Sulbutiamine.
100101 In one embodiment, the composition further comprises vitamin B5. In one embodiment, the composition further comprises vitamin B5 in the amount from about 25 mg to 350 mg. In one embodiment, the composition further comprises vitamin B5 in the amount of about 100 mg. In one embodiment, the vitamin B5 is selected from at least any one of, but not limited to, Pantethine, Pantothenic Acid, Pantothenol (Panthenol), Dexpanthenol and Calcium Pantothenate.
100111 In one embodiment, the composition further comprises vitamin B6. In one embodiment, the composition further comprises vitamin B6 in the amount from about 25 mg to 350 mg. In one embodiment, the composition further comprises vitamin B6 in the amount of about 100 mg. In one embodiment, the vitamin B6 is selected from at least any one of, but not limited to, Pyridoxine, Pyridoxal, Pyridoxine 5'-phosphate (P5P) and Pyridoxal 5'-phosphate (PLP).
100121 In one embodiment, the composition further comprises a methyl source, wherein the methyl source is selected from at least any one of, but not limited to, Betaine HC1, Betaine Anhydrous, Trimethylglycine (TNIG), Betaine Nitrate or Dimethylglycine (DNIG). In one embodiment, the composition further comprises methyl source in the amount from about 25 mg to 250 mg. In one embodiment, the composition further comprises methyl source in the amount of about 100 mg [0013] In one embodiment, the composition further comprises choline and magnesium sources, and also flavourings and sweeteners. In one embodiment, the composition further comprises the choline and magnesium sources in the amount from about 100 mg to 1000 mg. In one embodiment, the composition further comprises choline and magnesium sources in the amount of about 500 mg. In one embodiment, the choline source is selected from at least any one of but not limited to, Alpha Glycerol Phosphotyl Choline (Alpha GPC), CDP Citicoline, Phosphatidyl Choline or Choline Bitartrate. In one embodiment, the magnesium source is selected from at least any one of, but not limited to, Magnesium L-Threonate, Magnesium Orotate, Magnesium Citrate, Magnesium Taurate, Magnesium Bisglycinate, Magnesium Aspartate or Magnesium Lactate. In one embodiment, the composition is provided in at least any one or more forms include, but not limited to, capsules, tablets, liquid, liposomal, micelle, phospholipid or topical form, softgels, drinks, powder, medical food, intravenous and an oral composition.
[0014] In one embodiment, the composition further comprises nicotinamide mononucleotide (NMN) in the amount ranges from about 100 mg to 1000 mg taken into four equal doses, nicotinamide adenine dinucleotide (NAD) in the amount from about 100 mg to 1000 mg, pyrroloquinoline quinone (PQQ) in the amount from about 5 mg to 50 mg, coenzyme Q10 (CoQ10) in the amount from about 50 mg to 500 mg, piperine in the amount ranges from about 5 mg to 50 mg, vitamin B7 (Biotin) in the amount from about 0.25 mg to 5 mg, vitamin B9 (L-Methyl tetrahydrofolate-Ca) in the amount ranges about 0.25 mg to 5 mg, and vitamin B12 (Nlethylcobalamin) in the amount from about 0.25 mg to 5 mg.
[0015] In one embodiment, the composition further comprises nicotinamide Mononucleotide (NMN) in the amount of about 750 mg, nicotinamide Adenine Dinucleotide (NAB) in the amount of about 250 mg, pyrroloquinoline Qui none (PQQ) in the amount of about 20 mg, coenzyme Q10 (CoQ10) in the amount of about 200 mg, piperine in the amount of about 15 mg, vitamin B7 in the amount of about 1 mg, vitamin B9 in the amount of about I mg, and vitamin B12 in the amount of about 1 mg.
[0016] In another embodiment, the chemo-preventative and cytotoxic formulation is effective in treating coronavirus and other infections, cancer, PVFS/ME/CFS, fibromyalgia, improving immune, mitochondrial, stem cell and brain function, and reversing epigenetic aging, in an individual In one embodiment, composition further comprises Resveratrol, Pterostilbene, Quercetin, Baikal Skullcap, L-Theanine, Curcuminoids (Turmeric Extract), Lion's Mane Mushrooms, vitamin Bl, vitamin B2, vitamin B5, vitamin B6, Piperine and Zinc Complex.
[0017] In one embodiment, the composition comprises Resveratrol in the amount ranges from about 100 mg to 1000 mg, Pterostilbene in the amount ranges from about 100 to 750 mg, Quercetin in the amount ranges from about 100 mg to 750 mg; Baikal Skullcap in the amount ranges from about 50 mg to 500 mg; L-Theanine in the amount from about 50 mg to 500 mg; Curcuminoids (Turmeric Extract) in the amount from about 50 mg to 500 mg, Lions Mane Mushroom in the amount from about 100 mg to 1000 mg; vitamin BI in the amount from about 20 mg to 250 mg, vitamin B2 in the amount from about 25 mg to 350 mg; vitamin B5 in the amount ranges from about 50 mg to 500 mg; vitamin B6 in the amount ranges from about 25 mg to 350 mg; Piperine in the amount ranges from about 5 mg to 50 mg; and Zinc complex in the amount ranges from about 5 mg to 50 mg elemental zinc.
[0018] In one embodiment, the comprises further comprises D-ribose, and methyl source. In one embodiment, the composition comprises D-Ribose in the amount ranges from about 1 g to 10 g and methyl source in the amount from about 250 mg to 2500 mg. In one embodiment, the composition further comprises D-Ribose in the amount of about 5000 mg and the methyl source in the amount of about 1000 mg. In one embodiment, the zinc complex is selected from at least any one of but not limited to, Zinc Picolinate, Zinc Citrate, Zinc Gluconate, and Zinc Oxide. In one embodiment, the methyl source is selected from at least any one of, but not limited to, Betaine HCI, Betaine Anhydrous, Trimethylglycine (TMG), Betaine Nitrate or Dimethylglycine (DMG).
[0019] In one embodiment, the composition further comprises Taurine and Creatine. In one embodiment, the creatine source is selected from at least any one of, but not limited to, Creatine Monohydrate, Creatine Hydrochloride, Creatine Citrate, Creatine Magnesium Chelate and Creatine Nitrate. In one embodiment, the composition comprises Taurine in the amount ranges from about 150 mg to 1500 mg and creatine in the amount ranges from about 250 mg to 2500 mg.
In one embodiment, the composition further comprises Taurine in the amount of about 500 mg and creatine in the amount of about 1000 mg. In one embodiment, the composition is provided in at least any one or more forms include capsules, tablets, liquid, liposomal, micelle, phospholipid or topical form, soft gels, drinks, powder, medical food, intravenous and an oral composition.
[0020] In one embodiment, the composition comprises Resveratrol in the amount of about 300 mg, Pterostilbene in the amount of about 200 mg, Quercetin in the amount of about 250 mg, Baikal Skullcap in the amount of about 200 mg, L-Theanine in the amount of about 250 mg, Curcuminoids (Turmeric Extract) in the amount of about 200 mg, Lion's Mane Mushrooms in the amount of about 200 mg, vitamin B1 in the amount of about 100 mg, vitamin B2 in the amount of about 150 mg, vitamin B5 in the amount of about 250 mg, vitamin B6 in the amount of about 100 mg, Piperine in the amount of about 15 mg, and Zinc complex in the amount of about 15 mg elemental zinc.
[0021] In yet another embodiment, the composition comprises Alpha Lipoic Acid (ALA), AcetylL-C arnitine (ALCAR), N-Acetyl Cysteine (NAC), Ginkgo Biloba, Beta Glucans, Epigallocatechin 3-Gallate (EGCG), Green Tea Extract, Pomegranate Extract (incl. Ellagic Acid), Olive Leaf Extract (incl. Oleuropein and Hydroxytyrosol), Green Coffee Bean Extract (incl. Chlorogenic Acids), Theacrine and piperine. In one embodiment, the Beta glucans are selected from at least any one of, but not limited to Mushrooms, Oat, Barley or Yeast.
[0022] In one embodiment, the composition further comprises Methylliberine. In one embodiment, the composition further comprises Methylliberine in the amount from about 25 mg to 250mg. In one embodiment, the composition further comprises Methylliberine in the amount of about 100 mg. In one embodiment, the composition further comprises Adenosine disodium triphosphate in the amount from about 100 mg to 1000 mg. In one embodiment, the composition further comprises Adenosine disodium triphosphate in the amount of about 200 mg.
[0023] In one embodiment, the composition further comprises Shilajit (mineral pitch containing Humic & Fulvic Acids) In one embodiment, the composition further comprises Shilajit (mineral pitch containing Humic & Fulvic Acids) in the amount of about 25 mg to 250 mg. In one embodiment, the composition further comprises Shilajit (mineral pitch containing Humic & Fulvic Acids) in the amount of about 100 mg.
[0024] In one embodiment, the composition further comprises Alpha Lipoic Acid (ALA) in the amount from about 50 mg to 500 mg, Acetyl-L-Carnitine (ALCAR) in the amount from about 50 mg to 500 mg, N-Acetyl Cysteine (NAC) in the amount from about 100 mg to 1000 mg, Beta Glucans in the amount from about 50 mg to 500 mg, EGCG in the amount from about 50 mg to 500 mg, Green Tea Extract in the amount from about 50 mg to 500 mg, Pomegranate Extract (inch Ellagic Acid) in the amount from about 50 mg to 500 mg, Ginkgo Biloba in the amount from about 50 mg to 500 mg, Olive Leaf Extract (inch Oleuropein and Hydroxytyrosol) in the amount from about 50 mg to 500 mg, Green Coffee Extract (inch Chlorogenic Acids) in the amount from about 50 mg to 500 mg, Theacrine in the amount from about 25 mg to 250 mg, and Piperine in the amount ranges from about 5 mg to 50 mg.
[0025] In one embodiment, the composition further comprises Alpha Lipoic Acid (ALA) in the amount of about 200 mg, Acetyl-L-Camitine (ALCAR) in the amount of about 250 mg, N-Acetyl Cysteine (NAC) in the amount of about 300 mg, Beta Glucans in the amount of about 200 mg, EGCG in the amount of about 150 mg, Green Tea Extract in the amount of about 150 mg, Pomegranate Extract (inch Ellagic Acid) in the amount of about 200 mg, Ginkgo Biloba in the amount of about 200 mg, Olive Leaf Extract (inch Oleuropein and Hydroxytyrosol) in the amount of about 150 mg, Green Coffee Extract (incl. Chlorogenic Acids) in the amount of about 250 mg, Theacrine in the amount of about 100 mg, and Piperine in the amount of about 15 mg.
[0026] In one embodiment, the composition further comprises Vitamin BI. In one embodiment, the composition further comprises Vitamin B1 in the amount from about 25 mg to 250 mg. In one embodiment, the composition further comprises Vitamin B1 in the amount of about 100 mg. In one embodiment, the vitamin B I is selected from at least any one of but not limited to, Benfotiamine, Thiamine and Sulbutiamine.
[0027] In one embodiment, the composition further comprises Vitamin B5. In one embodiment, the composition further comprises Vitamin B5 in the amount from about 50 mg to 500 mg. In one embodiment, the composition further comprises Vitamin B5 in the amount of about 200 mg. In one embodiment, the vitamin B5 is selected from at least any one of but not limited to, Pantethine, Pantothenic Acid, Pantothenol (Panthenol), Dexpanthenol and Calcium Pantothenate.
[0028] In one embodiment, the composition further comprises vitamin B6. In one embodiment, the composition further comprises vitamin B6 in the amount from about 25 mg to 350 mg. In one embodiment, the composition further comprises vitamin B6 in the amount of about 100 mg. In one embodiment, the vitamin B6 is selected from at least any one of but not limited to, Pyridoxine, Pyridoxal, Pyridoxine 5'-phosphate (P5P) and Pyridoxal 5'-phosphate (PLP).
[0029] In one embodiment, the composition further comprises vitamin B7 Biotin. In one embodiment, the composition further comprises vitamin B7 Biotin in the amount from about 0.1 mg to 5 mg. In one embodiment, the composition further comprises vitamin B7 in the amount of about 1 mg [0030] In one embodiment, the composition further comprises vitamin B12. In one embodiment, the composition further comprises vitamin B12 the amount from about 250 mcg to 2.5 mg. In one embodiment, the composition further comprises vitamin B12 in the amount of about 1 mg. In one embodiment, the composition is provided in at least any one or more forms include capsules, tablets, liquid, liposomal, micelle, phospholipid or topical form, soft gels, drinks, powder, medical food, intravenous and an oral composition.
100311 Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
DETAILED DESCRIPTION OF EMBODIMENTS
100321 A description of embodiments of the present invention will now be given with reference to the below description. It is expected that the present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.
100331 The present invention generally discloses a formulation or composition for improving brain function and treating covid-19 (coronavirus infections) in an individual. The present invention directed to a nutritional supplement composition for improving cognition or rejuvenating ability and brain function and health of an individual using an active combination of substance selected from the group consisting of phytochemicals and bio-tech nutraceuticals and thereof 100341 According to the present invention, the nutritional supplement composition for improving stem cell production, proliferation & differentation, improving cognitive function of the human brain and also treating coronavirus infection and post-viral fatigue, comprising Nicotinamide Mononucleotide (NMN), Nicotinamide Adenine Dinucleotide (NAD), Pyrroquinoline Quinone (PQQ), Coenzyme Q10 (C0Q10), Piperine, vitamin B7 (Biotin), vitamin B9, vitamin B12. In one embodiment, the composition further comprises vitamin B5 and vitamin B6. In one embodiment the vitamin B5 is selected from at least any one of, but not limited to, Pantethine, Pantothenic Acid, Pantothenol (Panthenol), Dexpanthenol and Calcium Pantothenate. In one embodiment the vitamin B6 is selected from at least any one of, but not limited to, Pyridoxine, Pyridoxal, Pyridoxine 5'-phosphate (P5P) and Pyridoxal 5'-phosphate (PLP). In one embodiment, the composition further comprises choline and magnesium sources, and also natural fruit flavoring, mannitol, and sweeteners. In one embodiment, the choline source is selected from at least any one of, but not limited to, Alpha Glycerol Phosphoryl Choline (Alpha GPC), CDP Citicoline, Phosphatidyl Choline or Choline Bitartrate and also the magnesium source is is selected from at least any one of but not limited to, Magnesium L-Threonate, Magnesium Orotate, Magnesium Citrate, Magnesium Taurate, Magnesium Bisglycinate, Magnesium Aspartate or Magnesium Lactate. In one embodiment, the vitamin B9 is selected from at least any one of, but not limited to, L-Methyl tetrahydrofolate-Ca (calcium & non calcium salt of MethylFolate) and (65)-5-methyltetrahydrofolate (glucosamine salt) and the vitamin B12 is selected from at least any one of, but not limited to, Methylcobalamin, Adenocobalamin, Hydroxocobalamin, and Cyanocobalamin. In one embodiment, the nutritional supplement composition could be provided in the form of, but not limited to, capsules or a tablet or liquid, liposomal, micelle, phospholipid, or topical form, softgels, drinks, powder, medical food, intravenous and an oral composition.
[0035] In one embodiment, the composition is effective in the treatment of covid-19 (coronavirus) infections, improves health and mortality and morbidity outcomes in covid-19 (coronavirus infection), reduces discharge time, % progression to ICURTU, requirement of ventilators and intubation, lung damages, inflammation, and fibrosis. It is also effective in reducing covid-19 coagul opathi es, treats and prevents Coy and non-Coy caused thrombosis, protects against Sepsis, and also boosts recovery from Sepsis and septic shock. The composition is also effective in preventing/treating acute respiratory distress syndrome and also endotoxemia. In one embodiment, the composition is effective in reducing covid-19 transmission and preventing / treating post-viral and chronic fatigue syndrome / Myalgic Encephalomyelitis and fibromyalgia.
100361 In one embodiment, the composition has potent anti-viral properties against coronavirus and other viruses. It shows anti-viral activity against SARS-CoV-2 (Covid-19), inhibits coronavirus and viral entry, and also inhibits coronavirus and viral replication. In one embodiment, zinc ionophores in the composition effectively stops RdRp replication of coronayinis in humans by transporting zinc into cellular cytoplasm. It inhibits Covid-19 main protease, SARS-CoV-2 viral docking and reduces infectivity, and also inhibits cleavage of MERS-3CLpro Enzyme (Coronavirus). It also inhibits cellular entry of Sars-Cov-1 and enhances mucosal and respiratory immunity.
[0037] In one embodiment, the composition effectively modulates Sin] activity and mTOR Activity against coronavirus and inhibits SARS-CoV-2 entry via spike protein and also entry via 3CL protease inhibition. In one embodiment, the composition effects in preventing viral cycle via UPR modulation and acts as an anti-coyid-19 via Furin inhibition and PLpro inhibition. In one embodiment, the choline in the composition is essential for anti-viral immunity, and balancing choline levels in the brain, and increasing levels of the neurotransmitter acetylcholine, and formation of new brain cells and nerves via synthesis of phosphatidylcholine.
[0038] In one embodiment, the composition effectively protects respiratory tract from covid and non-coyid caused infections and acute lung injuries. The composition effectively reduces susceptibility to infection, improves influenzas mortality and morbidity outcomes, decreases incidence of infection in the elderly, reduces duration and severity of respiratory infections. In one embodiment, the composition is effective in alleviating symptoms of pneumonia, protects against cold and flu, reduces days of illness and work-related sick days. It also decreases incidence of influenza, prevents respiratory distress and dyspnoea, and also enhances response to flu vaccine 100391 In one embodiment, the composition is effective in reducing endothelial cell dysfunction (ECD), which is a main cause of morbidity in covid-19. Tn one embodiment, the composition effectively reverses CD38 associated chronic inflammation, which is also a main cause of covid19 morbidity and mortality. The composition effectively protects from covid caused thrombosis and blood clotting, reduces oxidized glutathione and double sulfide bonds into glutathione. The composition can chop up von Willebrand factor (VWF) and clotting factor 8 dimers into shorter strands, and directly reduce/solve blood clotting and thrombosis.
100401 In one embodiment, the composition is effective in increasing and enhancing innate and adaptive immune response, enhancing innate immune cell development, immune cell function & macrophage phagocytosis. The composition effectively promotes macrophage function, activates Sirtuin 1 for immune protection, and stimulates cholinergic system and acetylcholine production which is essential for immune function.
100411 In one embodiment, the composition is effective in boosting adaptive immune response, increasing development & proliferation of lymphocytes, enhancing T Cell differentiation and T cell killing activity, improving antibody response, preventing lymphocyte death & dysfunction, attenuating age-related DNA damage in lymphocytes and essential for haematopoiesis & leukocyte production. The composition effectively improves mitochondrial biogenesis & protects T Cells, 100421 In one embodiment, the composition is effective in regulating immune response to treat and prevent chronic inflammation and cytokine storm caused by covid-19 or other infections. The composition effectively regulates immune response to prevent covid & non-covid related cytokine storm & chronic inflammation. In one embodiment, the composition is effective in regulating lung immune response via activation of enzymes including PARP, ART and Sirtl, and controlling inflammation and cytokine release. The composition acts an anti-inflammatory and immunomodulatory for T-cells, and also Anti-inflammatory for dendritic cells. 1]
[0043] In one embodiment, the composition effectively protects from both covid & non covid related acute lung injury, regulates lung immune response and decreases airway inflammation, protects lungs from excessive pro-inflammatory cytokine response, and also protects from oxidative stress & free radicals. In one embodiment, the composition is effective in boosting white blood cell haematopoiesis for fighting infection via sirtuins, protecting upper respiratory tract from infection and lungs from excess inflammatory damage & fibrosis. The composition also maintains lung integrity and function post insult, reduces incidence duration and severity of Chronic Obstructive Pulmonary Disease (COPD), reduces rate of COPD exacerbations, and also alleviates chronic bronchitis. In one embodiment, the composition is effective in reducing COPD adhesions and improving respiratory function, and also restoring lung antioxidant levels and treating allergies such as asthma & allergic bronchitis.
[0044] In one embodiment, the composition acts as a chemo preventative and is cytotoxic to cancer cells, suppresses cancer stem cell (CSC) proliferation, targets and enhances anti-tumour T-cell response. In one embodiment, the composition is effective in inducing cancer cell apoptosis, preventing cancer progression and metastasis, promoting tumour cell death, epigenetic regulation for chemoprevention, and also promotes the P53 anti-cancer gene. In one embodiment, the composition is effective in reducing the chance of cancer recurrence and is essential for DNA methylation. The composition includes vitamin B, choline, and magnesium. to prevent deficiencies in these substances. The deficiency of vitamin B could lead to cancer. The deficiency in choline could lead to mitochondrial dysfunction and could be carcinogenic and magnesium deficiency is linked to colon & lung cancer. In one embodiment, the composition could effectively reverse multidrug resistance in cancer cells, and quercetin inhibits cancer cell cycle progression at a low dose, is synergistic with other chemotherapy agents, prevents chemotherapy toxic side effects, and has anti-cancer properties via DNA stabilization and repair.
[0045] In one embodiment, the composition is effective in preventing and treating different cancers such as, but not limited to, breast cancer, lung cancer, prostate cancer, ovarian cancer, hepatocellular melanoma & myeloma cancers, colon & pancreatic cancers. In one embodiment, the composition is effective in lowering breast cancer risk, inducing cytotoxicity in leukaemia & breast cancer cells, and suppressing cervical cancer cells. In one embodiment, the composition has anti-tumour activity in gallbladder carcinoma.
[0046] In one embodiment, the composition is effective in boosting stem cell production of all forms (proliferation) and stem cell maturation (differentiation). The composition increases stem cells maturing into functional cells (differentiation) and also increases neurogenesis (formation of new brain cells and neurons). In one embodiment, the composition rejuvenates stem cells and reactivates senescent (inactive) stem cells, improves stem cell function, rejuvenates gut adult stem cells & boosts intestinal stem cell populations, promotes stem cell self-renewal, improves cell survival & reprogramming via rock inhibition, and also enhances stem cell therapy for liver fibrosis. In one embodiment, the composition effectively reverses age-related decline in intestinal stem cells, improves neural stem cell self-renewal & proliferation, reprograms dysfunctional stem cells, promotes osteogenesis & inhibits apoptosis and aging of mesenchymal stem cells, and also stimulates bone marrow-derived mesenchymal stem/stromal cells (BMSC) proliferation & differentiation via ERK and P38. In one embodiment, the composition is effective in stimulating BMSC proliferation & differentiation, modulating neural crest stem cell development, and promoting proliferation & migration of neural stem cells. The composition effectively increases stem cell function in the treatment of damaged pancreas, stimulates hemopoietic stem cells, activates cardiac stem cells & improves myocardial regeneration, activates Sirtl for stem cell maintenance, aids in stem cell transplantation, and enhances cardiomyogenic stem cell differentiation.
100471 In one embodiment, the composition is effective in increasing mitochondrial function & biogenesis and enhancing energy production. The composition effectively reduces metabolic syndrome disorder & associated co-morbidities, increases mitochondrial biogenesis, stimulates mitochondrial biogenesis through cAMP & PGC-la expression, improves mitochondrial function & bioenergetics, corrects mitochondrial dysfunction, and also restores, protects, and boosts mitochondria In one embodiment the composition effectively prevents and treats chronic fatigue syndrome / myalgic encephalomyelitis and fibromyalgia through restoration of the antioxidant glutathi one, supporting methionine synthase, restoring function of the methyl ati on cycle, reversing mitochondrial dysfunction and supplying necessary cofactors and vitamins to alleviate deficiencies. In one embodiment, the composition effectively protects mitochondria via Sirt3, upregulates skeletal muscle mitochondrial biogenesis, modulates mitochondrial DNA content & alters lysine metabolism. Folates essential for mitochondrial translation and mitochondrial production of betaine In one embodiment, the composition effectively promotes mitochondrial biogenesis via PGC-la, induces mitochondrial biogenesis in endothelial (vascular) cells, upregulates gene expression for mitochondrial function, activates 1-10-1 signalling to alleviate mitochondrial damage, and protects mitochondrial integrity. In one embodiment, the composition is effective in alleviating age-associated decline in mitochondrial respiratory activity, attenuating mitochondrial dysfunction & biogenesis via AMPK / Sirtl, increasing brain mitochondrial biogenesis, restoring cellular homeostasis, and preventing/treating mitochondrial metabolism disorders. In one embodiment, the composition is effective in restoring Heme synthesis and reversing mitochondri al dysfunction.
100481 In one embodiment, the composition is effective in preventing and treating post viral fatigue syndrome, chronic fatigue syndrome, Myalgic Encephalomyelitis (ME) and fibromyalgi a. The composition effectively increases mitochondria biogenesis & efficiency, increases mitochondria fat & carbohydrate metabolism into ATP & helps in reducing weight, and vastly increasing energy production. In one embodiment, the composition effectively enhances strength, endurance & performance, improves sleep quality, reduces fatigue, prevents/treats post viral fatigue syndrome, chronic fatigue syndrome & fibromyalgia, treats chronic fatigue syndrome via altering mitochondrial bioenergetics, reduces muscle fatigue and also restores mitochondrial function in neurons.
[0049] In one embodiment, the composition is effective in increasing repair of DNA breakage, particularly double strand DNA breaks through Sirtl and PARP1 activity and, protecting DNA from toxic insults, oxidative stress, and age-related deterioration. The composition effectively increases telomeres length and telomerase activity, stabilizes DNA telomeres, restores normal gene expression, promotes DNA repair, prevents telomere shortening & cell apoptosis. Deficiency of certain ingredients within composition compromises DNA protection, repair & telomere length.
[0050] In one embodiment, the composition effectively and positively manipulates epigenetics, switching certain "good genes on" and "bad genes off'. In one embodiment, the composition effectively acts as a neuroprotective agent against various forms of dementia and prevents/treats Alzheimer's disease & neurodegeneration. In one embodiment, the composition could effectively reduce neuroinflammation, increase cognitive ability, increase short-& long-term memory formation & retrieval, increase synaptic strength and excitability (aka Long-Term Potentiation, LTP), improve learning and focus, reduce jet lag and increase cognitive function in humans. In one embodiment, the composition is effective in preventing and treating Parkinson's, protecting neural stem cells against neurotoxicity, and improving reasoning ability. The composition is effective in protecting against oxidative stress, cognitive injury excitotoxicity. The composition slows mental decline & dementia by preventing neuron loss, targets SARNIA to prevent neurodegeneration, may be beneficial in the case of epilepsy, advances stroke recovery and treats/slows progression of multiple sclerosis.
[0051] In one embodiment, the composition acts as an anti-nociceptive and relieves symptoms of pain. It also effectively increases angiogenesis (blood supply), enhances blood flow to vital organs & tissues, promotes healthy vision & prevents diseases related to the eyes. In one embodiment, the composition is effective in preventing and treating retinal degeneration, reducing macular degeneration risks, preventing/treating glaucoma and improving vision.
[0052] In one embodiment, the composition is effective in increasing dopamine, norepinephrine, epinephrine and serotonin production which boosts mood and helps treat symptoms of cognitive disorders and depression. In one embodiment, the composition effectively promotes good mood, is a strong natural anti-depressant, prevents/treats Schizophrenia, and also improves addictive behaviour.
[0053] In one embodiment, the composition effectively reverses physical and biochemical aspects of aging & reduces biological age in multiple quantifiable metrics. It increases feelings of youth, improves quality of life and improves mood & sense of wellbeing. boosts Sirtuin activity to mediate aging. The composition effectively boosts Sirtuin activity to mediate aging, activating Sirtl, Sirt3, and Sirt6. It also increases strength & endurance.
[0054] In one embodiment, the composition could effectively improve male fertility, reproductive health, sexual health, libido and increase mitochondrial function in Sertoli cells. In females it could effectively improve fertility, improve pregnancy outcomes, prevent preterm birth, prevent/treat nausea during pregnancy, relieve symptoms of PIVIS and some ingredients have been identified as important for pregnancy during the covid-19 pandemic. The composition effectively supports bone & joint health, prevents/treats osteoporosis and bone disease, prevents/treats arthritis via anti-inflammatory mechanisms, alleviates suppressed osteogeni c dysfunction, and improves ambulatory activity.
[0055] In one embodiment, the composition is effective in improving cosmetic appearance of skin, improving areas of skin damage, and reducing wrinkles and signs of aging. In one embodiment, the composition effectively supports healthy hair, skin and nails, promotes wound healing, restores hair colour, and helps treat acne. The composition could prevent or reduce headaches and migraines, enhance athletic performance, improve exercise endurance, increase strength and lean muscle mass, and enhance growth hormone production. In one embodiment, the composition could effectively improve mitochondrial function which in turn increases physical endurance and improves running performance.
[0056] In one embodiment, the composition is cardioprotective and is effective in treating heart disease and promoting heart health. The composition effectively reduces risk of heart disease, prevents/treats atherosclerosis, prevents/treats Anaemia, improves heart health by decreasing homocysteine, prevents/treats hypertension, improves cardiac mitochondrial fiinction, and also improves cholesterol metabolism, preventing/treating high cholesterol.
[0057] In one embodiment, the composition is effective in preventing, controlling, and treating diabetes, for example, type-1 diabetes and type-2 diabetes, as well as diabetic complications including diabetic neuropathy, diabetic nephropathy and diabetic retinopathy. The composition also effectively decreases insulin resistance, prevents/treats hyperglycaemia and aids in weight control, acting as an anti-obesity agent.
[0058] In one embodiment, the compostion is hepatoprotectA e and promotes liver & kidney health. The composition also effectively prevents/treats liver di seas including NAFLD (nonalcoholic fatty liver disease). Choline deficiency can lead to mitochondrial dysfunction & liver disease, which is prevented by the addition of choline to the formulation. In one embodiment, the composition effectively ameliorates and attenuates liver damage via enhancing mitochondrial respiration and prevents/treats renal disease.
[0059] In another embodiment, the nutritional supplement composition comprises nicotinamide mononucleotide (NMN) in the amount of about 100 mg to 1000 mg taken into four equal doses, nicotinamide adenine dinucleotide (NAD) in the amount of about 1000 mg to 1000 mg, pyrroquinoline quinone (PQQ) in the amount of about 5 mg to 50 mg, coenzyme Q10 (CoQ10) in the amount of about 50 mg to 400 mg, vitamin B7 (Biotin) in the amount of about 250 mcg 2.5 mg, vitamin B9 (L-Methyl tetrahydrofol ate-Ca / (6S)-5-methyltetrahydrofol ate) in the amount of about 250 mcg 2.5 mg, vitamin B12 (Methylcobalamin) in the amount of about 250 mcg 2.5 mg, vitamin B5 and vitamin B6 each in the amount of about 25 mg to 350 mg, each choline and magnesium sources in the amount of about 250 mg to 750 mg.
[0060] In yet another embodiment, the nutritional supplement composition comprises nicotinamide mononucleotide (NMN) in the amount of about 500 mg, nicotinamide adenine dinucleotide (NAD) in the amount of about 500 mg, pyrroquinoline quinone (PQQ) in the amount of about 20 mg, coenzyme Q10 (C0Q10) in the amount of about 200 mg, vitamin B7 (Biotin) in the amount of about 1 mg, vitamin B9 (L-Methyl tetrahydrofolate-Ca/) in the amount of about 1 mg, vitamin B12 (Methylcoba1amin) in the amount of about 1 mg, vitamin B5 and B6 each in the amount of about 100 mg, choline and magnesium sources in the amount of about 500 mg.
[0061] In one embodiment, multiple flavoured variants include fruit and other flavorings and mannitol/other sweeteners could be added to the nutritional supplement composition. In one embodiment, the composition further comprises resveratrol, pterostilbene, Quercetin, Taurine, Baikal Skullcap (with Baicalin), L-Theanine, vitamin Bl, vitamin B2, vitamin B5, vitamin B6, D-ribose, Piperine, and Zinc complex. In one embodiment, the composition further comprises Curcumin. In one embodiment, the composition comprises Curcumin in the amount from about 50 mg to 500 mg. In one embodiment, the composition further comprises Curcumin the amount of about 200 mg In one embodiment, the composition further comprises D-ribose, methyl source, and Zinc complex. In one embodiment, the composition comprises D-Ribose in the amount ranges from about 200 mg to 2000 mg and methyl source in the amount from about 100 mg to 1000 mg. In one embodiment, the composition further comprises D-Ribose in the amount of about 200 mg and the methyl source in the amount of about 200 mg. In one embodiment, the methyl source is selected from at least any one of, but not limited to, Betaine HC1, Betaine Anhydrous, Betaine Nitrate or Trimethylglcyine.
100621 In one embodiment, the composition comprises the resveratrol in the amount of about 300 mg, Pterostilbene in the amount of about 200 mg, Quercetin in the amount of about 250 mg, Curcumin in the amount of about 200 mg, Baikal Skullcap in the amount of about 200 mg, LTheanine in the amount of about 250 mg, vitamin B1 in the amount of about 100 mg, vitamin B2 (riboflavin) in the amount of about 150 mg, vitamin B5 in the amount of about 250 mg, vitamin B6 in the amount of about 100 mg, Piperine in the amount of about 150 mg, and Zinc complex in the amount of about 15 mg elemental zinc. In one embodiment, the zinc complex is selected from at least any one of but not limited to Zinc Picolinate, Zinc Citrate, Zinc Gluconate, Zinc Oxide.
100631 In another embodiment, the composition comprises alpha 1 poic acid (ALA), acetyl-Lcamitine (ALCAR), N-acetyl cysteine (NAC), beta glucans, ginkgo biloba extract, EGCG from green tea, theacrine, pomegranate extract (with Ellagic Acid), olive leaf extract (with Oleuropein & Hydroxytyrosol), lion's mane mushrooms, green coffee bean extract (with Chlorogenic Acids), shilajit (mineral pitch incl. humic & fulvic acids), vitamin B1, piperine, and zinc complex. In one embodiment, the composition further comprises Alpha Lipoic Acid (ALA) in the amount of about 200 mg, Acetyl-L-Camitine (ALCAR) in the amount of about 250 mg, N-Acetyl Cysteine (NAC) about 300 mg, Beta Glucans in the amount of about 200 mg, Ginkgo Biloba Extract in the amount about 200 mg, EGCG in the amount of about 150 mg, Green Tea Extract in the amount of about 150 mg, Theacrine in the amount of about 100 mg, Pomegranate Extract in the amount of 200 mg, Olive Leaf Extract in the amount of 150 mg, Lion's Mane Mushrooms in the amount of about 250 mg, Green Coffee Bean Extract in the amount of about 250 mg, Shilajit in the amount of about 100 mg, Vitamin B1 in the amount of about 100 mg, piperine in the amount of about 15 mg, and zinc complex in the amount of about 15 mg elemental zinc.
100641 In one embodiment, the preferred sources of beta glucans for supplement use is derived from yeast. f3-glucans found in the cell walls of yeast contain a 1,3 carbon backbone with elongated 1,6 carbon branches. In another embodiment, the sources of beta glucans for supplement use include, but not limited to, various medicinal mushrooms e.g. lingzhi/reishi, auaricus blazei muril, cordyceps, shitake, mitaike and lions mane are also alternative and good sources of beta glucans and other polysaccharides and the lesser sources of beta glucans are oat and barley, which feature 1,4 branches.
100651 In yet another embodiment, the composition comprises alpha lipoic acid (ALA), AcetylL-Carnitine (ALCAR), N-Acetyl Cysteine (NAC), beta glucans, EGCG, green tea extract, methylliberine, pomegranate extract (incl. Ellagic acid), olive leaf extract (incl. Oleuropein and Hydroxytyrosol), green coffee bean extract (incl, Chlorogenic Acids), adenosine disodium triphosphate, 1-carnosine, shilajit,l-theanine, theacrine, vitamin B1, vitamin B7 (biotin), piperine, and zinc complex. In one embodiment, the beta glucans is selected from at least any one of, but not limited to, Mushrooms, Oat, Barley or Yeast.
[0066] In one embodiment, the composition comprises the Alpha Lipoic Acid (ALA) in the amount ranges from about 100 mg to 500 mg, Acetyl-L-Carnitine (ALCAR) in the amount ranges from about 100 mg to 500 mg, N-Acetyl Cysteine (NAC) in the amount ranges from about 100 mg to 500 mg, Beta Glucans in the amount ranges from about 100 mg to 500 mg, EGCG in the amount ranges from about about 50 mg to 500 mg, Green Tea Extract in the amount ranges from about about 50 mg to 500 mg, Pomegranate Extract (incl. Ellagic Acid) in the amount ranges from about 100 mg to 500 mg, Olive Leaf Extract (incl. Oleuropein and Hydroxytyrosol) in the amount ranges from about 100 mg to 500 mg, Green Coffee Bean Extract (incl. Chlorogenic Acids) in the amount ranges from about 100 mg to 500 mg, the Adenosine disodium triphosphate in the amount ranges from about 100 mg to 500 mg, L-Carnosine in the amount ranges from about 100 mg to 500 mg, Shilajit in the amount ranges from about 50 mg to 500 mg, L-Theanine in the amount ranges from about 100 mg to 500 mg, Theacrine in the amount ranges from about 50 mg to 200 mg, Vitamin B1 in the amount ranges from about 50 mg to 500 mg, Vitamin B7 (biotin) in the amount from about 0.25 mg to 5 mg, and piperine in the amount from about 5 mg to 50 mg, and zinc complex in the amount from about 5 mg to 100 mg elemental zinc. In one embodiment, multiple flavoured variants include fruit/other flavorings and mannitol/other sweeteners could be added to the composition. In one embodiment, the composition further comprises methylliberine in the amount of about 25 mg to 250mg. In another embodiment, the composition further comprises methylliberine in the amount of about 100 mg.
[0067] In one embodiment, the benefits of consuming 500 mg of nicotinamide adenine dinucleotide (NAD) (and/or its precursor NMN) are, but not limited to, improves morbidity outcomes in covid-19 and combats coronavirus, controls and restores immune system, protects lungs, combats diabetes, chemopreventative, inhibits CD38 chronic inflammation and associated covid-19 mortality, prevents / treats post-viral chronic fatigue via correction of protein energy malnutrition (PEM) and improving function of the Krebs / citric acid / tricarboxylic acid cycle for ATP synthesis, and is also cytotoxic to cancer stem cells. The nicotinamide adenine dinucleotide plays a crucial role in innate arid adaptive immunity, and reduces endothelial cell dysfunction (ECD). It activates sirtuin 1, which regulates innate immune cell production and function and also protects lungs. The nicotinamide adenine dinucleotide also stimulates stem cell proliferation, and restores and activates senescent stem cells. The nicotinamide adenine dinucleotide targets and enhances anti-tumor T-cells, is chemopreventative, and is also cytotoxic to cancer stem cells.
[0068] The nicotinamide adenine dinucleotide also increases the production, proliferation & differentiation of stem cells, restores and activates senescent stem cells, controls neural stem cell self-renewal, reprograms dysfunctional stem cells, rejuvenates gut adult stem cells, improves cell survival and reprogramming, reverses age-related decline in intestinal stem cells, boosts intestinal stem cell populations, boosts mitochondria biogenesis, and increases mitochondrial efficiency. It also improves mitochondrial and stem cell function, corrects mitochondrial dysfunction, protects mitochondria from toxic and non-toxic insults and increases telomerase activity to lengthen DNA telomeres.
10069] It also increases the mitochondrial biogenesis process, prevents / treats chronic fatigue synrome / myalgic encephalomyelitis, repairs DNA double-strand breaks, increases telomerase activity, lengthens telomeres, stimulates dopamine synthesis, and aids in the treatment of depression, CFS/ME, fibromyalgia and post viral fatigue. The nicotinamide adenine dinucleotide also has anti-aging properties and strong anti-oxidant activity, combats diabetes, prevents/treats Alzheimer's, prevents fatty liver diseases, and promotes general health by boosting sirtuins.
[0070] In one embodiment, the benefits of consuming 500 mg of nicotinamide mononucleotide (NMN) are boosts the immune system, improves morbidity outcomes from covid-19, and also has anti-cancer properties. It also improves mitochondrial membrane function, restores and activates stem cells, and repairs DNA and telomeres The nicotinamide mononucleotide has anti-aging properties, aids in combating diabetes, increases strength and endurance, improves blood flow, helps with weight loss, prevents/treats Alzheimer's, promotes general health by boosting sirtuins, protects the heart, is integral for neuronal structure, boosts brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and also boosts memory and cognitive function in the brain [0071] In one embodiment, the benefits of consuming 20 mg of Pyrroloquinoline Quinone (PQQ) (one of the main benefits of PQQ is to increase NA D production & intra cellular levels, NAD then does the work) include, but not limited to, improves immune health, acts as a potent immunomodulator via regulating the immune system, prevents/treats cancer and helps treat obesity. It also decreases levels of pro-inflammatory cytokines such as IL-6, Cox-2, TNF-a, and IL-lb, significantly inhibits the production of NO and PGE2 and suppresses the expression of pro-inflammatory mediators. It also acts as an immunomodulator to prevent excessive inflammation and cytokine release in covid-19, aids in creating new mitochondria, neutralizes free radicals, boosts the immune system, is neuroprotective, improves breain function, memory and reasoning abilities, protects the heart, improves sleep and mood, alleviats symptoms of fatigue, and also decreases insulin resistance.
[0072] PQQ is essential for mitochondrial function and energy production. It may help in reducing the formation of melanoma cancers by reducing melanin-producing protein expression, inhibiting tyrosinase expression and reducing gene activity. PQQ also activates genes governing mitochondrial reproduction, protection and repair, protects neural stem cells, promotes osteogenesis and inhibits cell apoptosis i.e. unwanted cell death. It also triggers the DNA reading protein CREB, which plays a key role in growth and gene expression, upregulates skeletal muscle mitochondrial biogenesis, modulates mitochondrial DNA content, stimulates mitochondrial biogenesis through CAMP and PGC-la expression, restores normal gene expression, alters lysine metabolism, and also stimulates the production and release of nerve growth factors in cells that support neurons health. PQQ improves sleep quality, awakening response and treats ME/CFS. is neuroprotective against Alzheimer's, Parkinson's and cognitive injuries and promotes healthy memory formation and cognition in aging animals and humans. It also protects against excitotoxicity, which could cause many neurodegenerative diseases and seizures.
[0073] In one embodiment, the benefits of consuming 100 mg of coenzyme Q10 (CoQ10) promotes immune health. It has potent anti-microbial effects and is anti-viral against DNA & RNA viral infections, protects the respiratory system, decreases age-related immune decline, and improves fertility. It has anti-cancer properties, supports healthy heart function, increases ATP production for energy, is antioxidant and limits oxidative damage, and prevents lymphocyte death and dysfunction. CoQ10 prevents / treats fibromyalgia and PCFS/1VIE/CFS by increasing cellular ATP production via mitochodri al phosphorylation. CoQ10 reduces skin damage from internal and external agents by increasing energy production in skin cells and promoting antioxidant protection. It also improves mitochondrial function, helps decrease the inflammation that may occur during migraines, improves insulin sensitivity and regulates blood sugar levels. It is essential for the health of virtually all human tissues and organs due to its importance in ATP production and improves energy, augments the immune system and acts as an antioxidant.
[0074] In one embodiment, the benefits of consuming 100 mg of vitamin B1 (Benfotiamine/Thiamine/sulbutiamine) include, but not limited to, helps prevent diabetic complications, promotes cognitive improvement in Alzheimer's, promotes kidney health, and prevents/treats arthritis. It also protects the liver from oxidative damage due to alcohol consumption and lowers alcohol dependency. It also boosts the immune system, controls the bodies stress-related physiological impairments that may dampen the immune system, and enhances the macrophage response against Mycobacterium tuberculosis infections; deficiency has been linked to a significant decrease in immune function. As an anti-cancer agent, high intake of thiamine, as well as vitamin D, carotenoids, vitamin E and niacin, has been associated with decreased risk of bladder, colon, and prostate cancer. Vitamin B1 is essential in the formation of ATP as a cofactor in carbohydrate metabolism, it also preserves mitochondrial function, specifically in the brain during insult, and accelerates healing and nuerovascularisation in ischaemia induced injury and improves symptoms of fibromyalgia and PVFS/ME/CFS. In the brain, vitamin B1 is essential for neurotrasmitter formation, specifically acetylcholine, and supports the structure and function of nuerons and neuroglia, essental for brain function. Benfotiamine also prevents/treats Wernicke-Karsakoff Syndrome (delirium), which is caused by thiamine deficiency, and prevents/treats Alzheimer's; in clinical trials 300mg daily for 18 months improved Alzheimer's patients cognitive ability. Benfotiamine and Sulbutiamine are fat soluble and can cross the blood brain barrier. Normal Thiamine is not lipid soluble and has trouble in rectifying low B1 levels in the brain.
[0075] In one embodiment, the benefits of consuming 100 mg of vitamin B2 (Riboflavin) include, but not limited to, immune system booster, has anti-viral properties and may help reduce covid-19 transmission. It also boosts the innate immune response, prevents/treats sepsis and improves sepsis mortality rates, all important in covid-19. It both activates immune cells and is immunomdulatmy & anti-inflammatory, so controls an excessive immune response. A high dose of Riboflavin was also indicated to decrease LPS-induced mortality by increasing the expression of heat shock protein 25 (HSP25). Supplementation could boost macrophage function and phagocytosis of pathogens.
[0076] It also has anti-cancer properties, prevents toxic chemotherapy side effects and could increase the efficacy of chemotherapy agents. In the body it is metabolized to flavin mononucleotide (FNIN) and flavin dinucleotide (FAD) which are cofactors in ATP formation and are essential for energy production Therefore riboflavin prevents/treats energy metabolsim disorders, alleviates mitochondria] dysfunction, treats associated neuropathies and can successfully treat ME/CF S, improving tiredness, muscle weakness and short-term memory. In the brain, thiamine is essential in the maintenance of nerve myelin sheaths and nerve conduction, prevents/treats neuropathies such as Multiple Sclerosis, boosts dopamine levels and helps treat traumatic brain injuries. In the case of Parkinson's, riboflavin ameliorates oxiative stress, mitochondrial dysfunction, neuroinflammati on and glutamate excitotoxi city, which improves motor capacity in patients. Vitamin B2 also acts as an anti-nociceptive and relieves pains.
[0077] In one embodiment, the benefits of consuming 100 mg of vitamin B5 include, but not limited to, immune boosting properites such as enhancing macrophage and T cell response, and anti-cancer properties, particularly for ovarian cancer, such as slowing tumor progression and decreasing metastases. It also has anti-obesity and weight controlling properties, lowers cholestrol and prevents/treats diabetes. Vitamin B5 aids in wound healing, restores hair color and helps treat facial acne. Vitamin B5 is essential for many human processes and also reduces risk of cardiovascular disease through lowering LDL cholesterol and triglycerides and raising HDLcholesterol. In neurodegenerative disease, Vitamin B5 restores acetyl Coeznyme-A synthesis (CoA), improves mitochondrial function, rescues brain function, increases lifespan and counteracts gene dysregulation, so is useful in Alzheimer's treatment. Vitamin B5 supplementation increases the production of the neurotransmitter acetylcholine from choline sources, as well as the neurotransmitters epinephrine and serotonin. It helps modulate cortisol levels produced in the adrenal glands, increasing coping mechanisms with stress and lessening depression.
100781 Vitamin B5 is converted Coenzyme-A (CoA),which is an essential cofactor in over 70 enzymatic pathways, including metabolizing amino acids to pyruvate to enter the Krebbs cycle for ATP synthesis. Energy generation for relief of Chronic Fatigue & ME being one of the crucial inventions. In one embodiment, the vitamin B5 could be Pantethine or Pantothenic Acid. The preferred form Pantethine is more bioavailable and shows higher efficacy.
100791 In another embodiment both Panthethine and Pantothenic acid are used. Pantethine creates twice as much CoA compared to Pantothenic Acid. Pantothenic acid also enhances adrenal function and modulates inflammation.
[0080] In one embodiment, the benefits of consuming 100 mg of vitamin B6 (P-5-P) include, but not limited to, treatment in severe casis of covid-19, mitigate covid-19 immune supression, prevent associated covi d-19 blood clotting & mortality and overall booting the immune response. In severe covid-19 patients, especially the elderly or those with underlying health conditions, vitamin B6 may prevent cytokine hypersecretion and blood clotting, improve endothelial integrity and prevent lymphopenia. It also promotes brain health and reduces cognitive decline in neurodegenerative disease, improves moods and combats depression. It promotes healthy red blood cell production, reduces risk of heart diseases, treats inflammation & arthritis and promotes eye health. In women it prevents nausea during pregnancy and relieves symptoms of premenstrual syndrome (PNIS). Vitamin B6 has anti-cancer properties as it is a potent antioxidant and modulates gene expression, so plays a multifaceted role in carcinogenesis. It is essential for mi tochondri al function and protects from oxidative stress. P-5-P (PLP) is the prefered form of of vitamin B6 over pyridoxine. P-5-P is more bioavailable and shows higher efficacy particularly w.r.t. neurodegeneration and the brain in general. P5P is a cofactor in making serotonin and the synthesis of dopamine from dopa. Deficiency is associated with the development of N1E/CFS and vitamin restoration significantly improves symptoms of disease, measured by the Fibro Fatigue Scale, and Quality of Life in patients.
[0081] In one embodiment, the benefits of consuming 1 mg of vitamin B7 (H Biotin) include, but not limited to, has anti-inflammatory properties and acts as an immunomodulator in T-cells It regulates gene expression and metabolism, and restores mitochondrial function in neurons is used in hemaglobin synthesis. Vitamin B7 also reverses mitochondrial dysfunction and treats and slows the progress of multiple sclerosis. Biotin (vitamin B7) is essential for human health because of its involvement, as a cofactor, in a variety of critical cellular metabolic reactions as well as heme synthesis for oxygenation & respiration. It also acts as an anti-inflammatory for dendritic cells (DCs) which play an important role in improving age-associated progressive decline in adaptive immune responses, loss of immune tolerance, and development of chronic inflammation.
100821 In one embodiment, the benefits of consuming 1 mg of vitamin B9 (MethylFolate) include, but not limited to, anti-viral properties including prevention of covid-19 via furin inhibition, increases resistance to infection, boosts the immune system, protects and supports the respiratory system, controls cytokine release & attendant inflammation to mitigate covid-19 mortality, and is also essential for haematopoesis and leukocyte production. It also reduces risk of cancer and promotes stem cell proliferation as well as neural crest stem cell development. Vitamin B9 is essential for mitochondri al translation prevents/treats mi toch on dri al disorders; increased levels are associated with longer telomeres and DNA methylation. Vitamin B9 prevents / treats ME/CFS and fibromyalgia via restoration of methylation function and the Krebs / citric acid cycle for energy production.
100831 Vitamin B9 aids in treating diseases such as schizophrenia, Alzheimer's, mania (mental illness), diabetic neuropathy, cardiovascular diseases, improves pregnancy outcomes and also prevents preterm birth, boosts immune system by increasing resistance to infections and combats depression, impacts cancer risk and is essential for one-carbon metabolism. It also increases resistance to infection and boosts immune system. It also has anti-viral properties and also protects and supports respiratory system. The vitamin B9 controls inflammation and also controls cytokine release. It also essential for the maintenance of Regulatory T Cells, to prevent autoimmunity.
100841 In one embodiment, the benefits of consuming 1 mg of vitamin B12 (Methylcobalamin) include, but not limited to, has therapeutic potential in covid-19 (coronavirus) and may help with acute respiratory distress syndrome. It also plays and supports in immune system regulation and improves T-cell function. Vitamin B 12 acts as chemoprevention and cytotoxicity, improves DNA health and telomere length, and also regulates DNA methylation and disease. In ME/CFS, Vitamin B12 supports methylation and methionine synthase, to alleviate methlyation cycle blocks and to support the conversion of homocysteine to methionine to improve smptoms of the disease.
[0085] Vitamin B12 plays an important role in immune system regulation. It also aids in producing red blood cells and preventing anemia, prevents major birth defects and support bone health and also prevent osteoporosis, reduces risk of macular degeneration and improve mood and symptoms of depression, improves brain health by preventing the loss of neurons and also improves heart health by decreasing homocysteine, and supports healthy skin, hair, and nails.
[0086] In one embodiment, the benefits of consuming 500 mg of Alpha GPC/CDP citicoline/choline bitartrate include, but not limited to, fights against covid-19 (coronvirus) and it is essential during pregnancy and also essential for anti-viral immunity and immune function. It protects against sepisis, also improves cholinergic system and acetylcholine function. Alpha GPC/CDP citicoline/choline bitartrate is also essential for macrophage response and treats Endotoxaemia. It also reduces the risk of carcinogenic, mitochondrial, and liver diseases and also combats mitochondrial dysfunction.
[0087] Alpha GPC/CDP citicoline/choline bitartrate is also essential in methylation and mitochondrial production of betaine, enhances growth hormone production, improves memory capacity, learning and focus, and also athletic performance. It also advances stroke recovery and benefits for epileptic patients.
[0088] In one embodiment, the benefits of consuming of a magnesium source such as Magnesium L-Threon ate include, but not limited to, improves morbidity in covid-19 patients and also improves the immune system. It also reduces the risk of cancer, such as breast cancer, colon cancer, lung cancer, and reduces magnesium linked to inflammation and carcinogenesis. It also essential for mitochondrial homeostasis, regulates and improves energy production, and also improves mitochondrial and cardiac function, cognitive function. Low red cell magnesium is a clinical manifestation of CFS, restoring magnesium in such patients successfully reduces symptoms of disease including improved energy, emotional state and a decrease in pain. Magnesium LThreonate improves learning skills and memory, sleep by controlling nerve activity in the brain.
[0089] In one embodiment, the benefits of consuming 250 mg of Resveratrol include, but not limited to, acts as an immunomodulator and an anti-coronavirus via Sirtuinl and mTOR, boosts immune activity, has anti-viral and antibacterial properties. It also protects from cytokine Storm and against ventilator induced lung damage and also protects T-Cells. It has respiratory anti-inflammatory and anti-fibrotic properties. Resveratrol protects the respiratory system and also respiratory anti-apoptotic effect. It also has substantial anti Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) & MERS-CoV activity.
[0090] Resveratrol has anti-cancer properties, induces cancer cell apoptosis, and reverses multi-drug resistance in cancer cells. It also aids in renewing and differentiating stem cells, activates Sirtl for stem cell maintenance, and also activates cardiac stem cells. Resveratrol improves myocardial regeneration and regeneration of mesenchymal stem cell aggregates, and also stem cell function in the treatment of damaged pancreas. It also promotes mitochondrial biogenesis via PGC-la, improves mitochondrial biogenesis and its function, and also induces mitochondrial biogenesis in endothelial (vascular) cells. Resveratrol prevents / treats post-viral fatigue, PVFS/ME/CFS by enhancing antioxidant status and improving hippocampal atrophy through enhancing neurogenesis and inhibiting cellular apoptosis. Resveratrol improves physical endurance, telomere length, reverses cellular senescence, ameliorates age-related metabolic disease, and also lengthen lifespan.
100911 Resveratrol aids in combating Type 1 & 2 diabetes, improves neuron function, heart health, and also prevents Alzheimer's disease. It has antioxidant properties and anti-cancer properties, treats parkinson's disease, alleviates liver disease, shows positive effect on cholesterol, and also lengthens lifespan. It has anti-viral activity against Epstein-Barr virus one of the main causes of PVES/A4E/CFS, inducing caspase-dependent apoptosis by arresting cell-cycle progression in G1 phase, and strongly induced apoptosis in EBV(-) and latency I EBV(+) cells.
100921 In one embodiment, the benefits of consuming 200 mg of Pterostilbene include, but not limited to, activates against SARS-CoV-2 and it has anti-viral and antimicrobial activities and it supports and protects respiratory system. It could help protect against acute lung injury via induction of heme oxygenase-1. The pterostilbene interacts with the C-terminal of Si domain on the spike glycoprotein found on SARS-CoV-2, with a greater affinity than hydroxychloroquine. The pterostilbene boosts immune response and fights against oxidative stress and inflammation and it also acts as an immunomodulator. Pterostilbene is a potent proteasome inhibitor that suppress expression of genes and production of inflammatory. It acts as a natural anti-cancer agent due to its antioxidant and antineoplastic properties and prevents/treats different cancers such as lung cancer, breast cancer, prostate cancer, hepatocellular melanoma, pancreatic cancers, and also treats colon. Pterostilbene suppresses generation of breast cancer cells and cervical cancer cells, and targets cancer stem cells. It has apoptotic activity against cancer and also non-apoptotic effects against cancer, inhibits telomerase for chemoprevention, and shows epigenetic regulation for chemoprevention. The pterostilbene has been found to be beneficial in improving the function of normal cells and inhibiting malignant cells.
[0093] It also aids in improving cholesterol levels, blood pressure, and blood sugar levels, improves insulin sensitivity and protects against diabetes and metabolic syndrome, reduces oxidative stress and the production of reactive oxygen species and boost weight loss, aids in improving eye health and preventing diseases related to neurological disease, for example, Alzheimer's, liver diseases, and arthritis, combats atherosclerosis and increases muscle mass and strength, and also has anti-cancer properties. It as a natural anti-cancer agent due to its antioxidant and antineoplastic properties 100941 In one embodiment, the benefits of consuming 250 mg of quercetin include, but not limited to, fights against coronavirus and inhibits SARS-3CL Protease Activity and SARS-CoV molecular docking. The quercetin modulates the cellular unfolded protein response (UPR). Coronaviruses utilizes the UPR to complete different stages of viral life cycle during infection. Thus, modulating the UPR could be an effective strategy to fight against the coronavirus. The quercetin reduces infectivity of target cells and replication in a wide variety of respiratory viruses such as HSV-1, HSV-2, AdV-3, AdV-8, AdV11, Coronavirus, SARS, parainfluenza type 3, HRSV, and rhinovirus. The quercetin has antibacterial effects have been exhibited amongst almost all bacterial strains including those in the digestive, respiratory, urinary and skin systems. It also reduces viral respiratory infection and effective in respiratory tract infections. Zinc ionophore activity of quercetin stops RdRp Replication of coronavirus in humans, boosts immune system, prevents/treats respiratory infection and also supports lungs, promotes cytokine modulation and protects from cytokine storm.
100951 Quercetin has anti-cancer properties and inhibits cancer cell cycle progression at low dose, shows synergistic action with other chemotherapy agents, and also induces cytotoxicity in Leukaemia and breast cancer cells. It also prevents/treats ovarian cancer and also suppresses prostate cancer & prevent metastasis.
100961 It also stimulates bone marrow stem cell proliferation and differentiation and also BMSc proliferation and differentiation via ERK and P38. Quercetin promotes proliferation and migration of neural stem cells, protects and modulates mitochondrial function & biogenesis, increases mitochondrial biogenesis and exercise endurance, attenuates mitochondria] dysfunction and biogenesis via AMPK/Sirtl, and also improves mitochondrial function in brain injury. It also increases brain mitochondrial biogenesis. Quercetin treats PVFS/MIE/CFS via enhancement of antioxidation and glutathione status, and alleviates associated vascular imparments and reduces inflammatory cytokines. It also has anti-viral activity against the Epstein-Barr virus -a major cause of PVES/ME/CFS.
100971 Quercetin also fights with free radicals arid reduces inflammation, prevents spread of cancerous cells and tumor growth, combats aging and lowers the risk of neurodegenerative disorders, exhibits both antibacterial and antiviral activity, thereby enhancing immunity and preventing infections, relieves from allergy and acts as a natural antihistamine by inhibiting release of histamine from mast cells, prevents heart related diseases and promotes healthy blood pressure and blood sugar, and stimulates brain and muscle mitochondrial biogenesis by endurance exercise.
100981 The combination of Resveratrol, Quercetin & Pterostilbene is highly synergistic, Giving greater efficacy than when used singly. Piperine substantially enhances bioavailability and efficacy of the combination.
100991 In one embodiment, the benefits of consuming 200 mg of taurine include, but not limited to, protects from cytokine storm and acts as an immunomodulator and has anti-coronavirus properties. The taurine controls immune inflammation and supports respiratory system and also promotes pathogen defense. The taurine has a beneficial molecule for stroke and cardiovascular disease and plays an important role in intracellular calcium levels. It promotes immunological defense in humans against pathogens including coronavirus through enhancing metabolism and functions of monocytes and macrophages. Taurine has anti-cancer properties and been shown to have activity against breast cancer and other tumours and fights against diabetes and promotes heart health. It also helps with depression and diabetes, boosts exercise performance, promotes eyes health, liver health, neuroprotective, and brain health, and also may exhibit antidepressant properties.
1001001 In one embodiment, the benefits of consuming 100 mg ofbetaine / trimethylglycine include, but not limited to, has anti-viral properties and anti-cancer properties and also acts as an immunomodulator and regulator. It also supports the respiratory system, reduces inflammation (anti-inflammatory), and also controls the immune system. Trimethylglycine treats high homocysteine, alleviates fatty liver and liver diseases, acts as cardioprotective, enhances exercise performance and mood and cognitive function of the brain. It also increases lean muscle mass and combats against diabetes.
1001011 Trimethylglycine aids in methlyation of DNA. Abbherant methylation is a major cause of cancer. Optimum DNA methylation triggers many epigenetic switches highly influential to longevity and anti-ageing. It also enhances the process of methylation to protect and treat mitochondrial dysfunction and PVFS/ME/CFS [00102] In one embodiment, the benefits of consuming 200 mg of baicalin (Baikal Skullcap Extract) include, but not limited to, has anti-coronavirus activity and fights against coronavirus and acts a SARS-CoV2 PLpro inhibitor. The baicalin has anti-viral and anti-microbial activities and also has anti-cancer properties. The anti-cancer effects down to ability for free radical scavenging, attenuation of NF-kB activity, modification of cell cycle gene expression, COX-2 gene expression control, and has anti-viral capabilities. The baicalin has potent anti-inflammatory and anti-oxidant properties and also neuroprotective effects. It has the ability of a chemical substance to prevent damage to the liver (hepatoprotective) and aids in treating liver problems, and also enhances mitochondrial function. Baicalin has anti-cancer properties and anti-tumor activity in gallbladder carcinoma, induces cancer cell apoptosis and inhibits proliferation, also promotes neural stem cell proliferation and differentiation, aids in stem cell transplantation, and also induces colon cancer apoptosis. It also protects from mitochondrial dysfunction and associated disorders. In one embodiment, the baicalin could be extracted from, but not limited to, Baikal skullcap plant. The baicalin reduces infectivity of target cells and replication in a wide variety of viruses including Epstein-Barr virus implicated in PVFS/ME/CFS, and has efficacy in PVFS/ME/CFS.
[00103] In one embodiment, the benefits of consuming 200 mg of L-Theanine include, but not limited to, boosts immune system function and aids in decreasing the incidence of upper respiratory tract infections. It also supports the respiratory system, enhances vaccine in elderly, fights with viral common cold, and also protects from influenza. The consumption of L-theanine is beneficial for people with high levels of anxiety and helps people to focus better during demanding tasks. It has anti-cancer properties and also lowers blood pressure, improves sleep quality, and helps in relieving sinusitis symptoms. L-Theanine promotes neural stem cell proliferation, differentiation, and neurogenesis, attenuates injury in neural stem cells & protects from cognitive impairment, increases mitochondrial function in Sertoli cells, and also prevents/treats hypertension. It is a powerful nootropic. In one embodiment, the L-theanine is an amino acid found most commonly in tea leaves and in small amounts in Bay Bolete mushrooms.
[00104] In one embodiment, the benefits of consuming 200 mg of alpha lipoic acid include, but not limited to, reduces covid-19 mortality and morbidity rates. It prevents coronavirus entry via main protease inhibition and alleviates Dyspnoea and respiratory symptoms affected due to covid-19 (coronavirus). The alpha lipoic acid boosts immune response and also prevents cytokine storm and respiratory distress. It acts as an immunomodulatory and supports the immune system by protecting from ROS and oxidative stress, as well as downregulates in autoimmune disorders. The alpha lipoic acid lowers inflammatory markers in patients suffering from metabolic syndrome and related disorders. It decreases oxidative stress, thus improves integrity of red blood cells and elevates glutathione levels for antioxidation, consequently preventing / treating disorders such as ME/CFS. The alpha lipoic acid has free radical scavenging properties, as well as a radical generator, are considered important as a potential use for cancer therapy. It has anti-cancer properties and also increases apoptosis of cancer cells. In addition, patients with pancreatic cancer were treated with a combination of low-dose naltrexone (LA-N) and ALA, which showed to have an improved effect on life expectancy. ALA inhibits initiation & promotion of carcinogenesis. The alpha lipoic acid increases stem cells, for example, mesenchymal stem cells (MSCs), which are contribute to tissue repair in vivo and form an attractive cell source for tissue engineering. It is essential for mitochondrial function, promotes Neuroproliferation after a stroke, increases mesenchymal stem cell survival and proliferation, enhances neural stem cell survival post-transplantation, alleviates suppressed osteogenic dysfunction, and also enhances cardiomyogenic stem cell differentiation.
[00105] It enhances life span and promotes longevity, weight loss, and helps to combat diabetes, promotes cognitive health and memory, protects neural tissue and reduce peroxidation via metals, which may benefit the pathophysiology of Alzheimer's, promotes healthy nerve function and lowers risk of heart diseases, and reduces inflammation and signs of aging. The alpha lipoic acid improves age-associated mitochondrial & cognitive dysfunction and age-associated decline in mitochondrial respiratory activity, mitochondrial function & running performance, protects mitochondrial enzymes, increases mitochondrial biogenesis and boosts energy, and also decreases the age-related oxidative mitochondrial decay.
1001061 In one embodiment, the benefits of consuming 200 mg of Acetyl-L-Carnitine (ALCAR) include, but not limited to, boosts immune health and has anti-viral and anti-bacterial properties. It also has anti-cancer properties and prevents cytokine storm. The Acetyl-L-Carnitine enhances mitochondrial function and energy production and reduces fatigue and also increases ambulatory activity. ALCAR is essential for transportaion of fatty acids into the mitochondria for energy generation, and has shown to improve symptoms of PVFS/ME/CFS including improvement in physical function, mental fatigue and cognitive status. It also improves brain function and aids weight loss, enhances heart health and exercise performance by increasing oxygen supply to muscles, and also reduces diabetic symptoms and improves male fertility.
[00107] It also prevents immune system dysfunction, prevents sepsis, shows protective effect in human lymphocytes, and has anti-cancer properties. ALCAR has successfully inhibited angiogenesis by downregulating vessel growth factors related to cancer cells, enhances mesenchymal stem cell neurogenesis, increases telomere length and telomerase activity and methylation, modulate stem cell differentiation via mitochondrial metabolism, and also promotes bone-marrow-derived mesenchymal stem cell production. It also increases telomerase activity in mesenchymal stem cells, restores mitochondrial function and ambulatory activity, boosts mitochondrial function and also prevents/treats cardiovascular disease, regulates mitochondrial homeostasis in the brain, and also enhances mitochondrial function.
[00108] The Acetyl-L-Carnitine improves mitochondrial function and energy production and reduces fatigue and also increases ambulatory activity. Curcumin increases the antioxidant capacity of the body, improves brain function, lowers the risk of heart disease, prevents & treats Alzheimer's disease, treats symptoms of arthritis, fights depression, helps delay aging and fights against age-related chronic diseases [00109] In one embodiment, the benefits of consuming 300 mg of N-Acetyl Cysteine (NAC) include, but not limited to, improves covid-19 morbidity, reduces oxidative stress associated with covid-19, increases lung glutathione, reduces respiratory blood clot and incidence of chronic obstructive pulmonary disease (COPD), and also improves of respiratory function. It also reduces rate of COPD exacerbations, modulates inflammation in COPD patients, increases antioxidant capacity in COPD, reduces COPD adhesions and symptom severity in COPD, and also decreases lung function decline in COPD. N-Acetyl Cysteine also alleviates chronic bronchitis, reduce sick days associated with bronchitis, may help with viral pneumonia, and also blocks HIV in acute and chronic infection.
[00110] It acts as an antioxidant, prevents and treats kidney and liver damages, improves fertility, and also improves psychiatric disorders and addictive behavior. N-Acetyl Cysteine also stabilizes blood sugar, improves cognition and prevents and treats neurological disease, influenza, and pneumonia and also reduce heart disease risk, liver and kidney damages It also improves psychiatric disorders and addictive behavior, improves cognition and prevents/treats neurodegenerative disease, improves male and female fertility, prevents / treats 1VIE/CFS, and also stabilizes blood sugar and improve insulin resistance.
[00111] In one embodiment, the benefits of consuming 200 mg of Ginkgo Biloba extract include, but not limited to, boosts anti-viral and immune system and protects respiratory system and also prevents lung fibrosis. It also controls lung inflammation and aids in treating chronic obstructive pulmonary disease and also beneficial in acute lung injury. The Ginkgo biloba has potent antioxidant and immunostimulatory properties. It also possesses inhibitory effects on various human and animal cancer cells. It has anti-cancer anti-proliferative properties. It also has proven efficacy against ME / CFS. Ginkgolic acids some of the main active constituents of Ginkgo Biloba extracts inhibits fusion of enveloped viruses of all three classes of fusion proteins including HIV, Ebola virus (EBOV), influenza A virus (IAV) and Epstein-Barr virus (EBV), as well as inhibiting HSV-1 (Herpes Simplex Virus 1) and ZIKV (Zika virus), an RNA virus 1001121 It also neutralizes the damage effects of free radicals and oxidative damage, thereby promoting longevity, prevents / treats ME/CFS by reducing oxidative stress in cells, fights against inflammation and promotes heart and circulatory health, supports neurotransmitter, neurogenesis, and neuroprotection and also increases hippocampal (brain) cell proliferation by up to 80%, which is more potent with the addition of quercetin, enhances cognition and alleviates Alzheimer's and dementia, reduces anxiety and depression and also enhances memory and learning, supports eye health and vision, and also treats headaches and migraines, promotes lung health and improves symptoms of asthma and other inflammatory respiratory diseases like chronic obstructive pulmonary disease (COPD), treats both the physical and psychological symptoms of premenstrual syndrome (PM S), and also improves sexual health and libido and treats sexual dysfunction.
1001131 In one embodiment, the benefits of consuming 150 mg of EGCG from green tea extracts include, but not limited to, acts as an Immunostimulatory, decreases incidence of influenza, anti-viral against RNA viruses, and also promotes lymphocyte proliferation and differentiation. It also promotes macrophage phagocytosis, enhances anti-infective cytokine production, improves influenza mortality outcomes, and effective against ssRNA (+) viruses including covid-19 (coronavirus). It acts as an immunomodulator, protects immune cells from inflammation and oxidative stress, and also reduces incidence and severity of flu. EGCG also reduces oxidative stress and lipid peroxidation, and has shown to improve biocheial and behavioural parameters in ME/CFS. In one embodiment, green tea extract various grades include, but not limited to, 95% Polyphenols, 98% Polyphenols, 80% Catechins, 50% EGCG. EGCG inhibits Epstein-Barr virus (EBV) spontaneous lytic infection at the DNA, gene transcription and protein levels and can improve certain ME/CFS pathology.
[00114] In one embodiment, the benefits of consuming 100 mg of Methylliberine include, but not limited to, boost energy without side effects of caffeine, enhances mood, focus, and motivation and improves performances. Exerts effects on dopamine receptor and adenosine inhibition to increase cellular energy with limited side effects. Successfully crosses the blood brain barrier and activates neurons.
[00115] In one embodiment, the benefits of consuming 100 mg of Theacrine include, but not limited to, stimulate adenosine and dopaminergic signalling similar to caffeine, antinociceptive, increase alertness and may reduce stress. It also protects from oxidative stress and has anti-inflammatory properties.
[00116] In one embodiment, the benefits of consuming 200 mg of Pomegranate Extract (with Ellagic Acid) include, but not limited to, has anti-viral and anti-bacterial properties and anti-inflammatory effect. It also protects from oxidative stress immune system antioxidant effects, blocks RNA virus replication, protects lungs from inflammation and fibrosis. Ellagic Acid (EA) enhances mucosal immunity, EA and gallic acid (GA) reduces acute lung injury (ALT) Pro-inflammatory cytokine damage, decreases airway inflammation, may help with sepsis. It also increases antioxidant enzymes and the GA protects against pulmonary fibrosis and COPD, promotes cytokine modulation, and also protects respiratory system, treats lung inflammation, and also cytokine storm.
[00117] In one embodiment, the benefits of consuming 200 mg of curcumin include, but not limited to, has anti-coronavirus activity and anti-viral activity and also inhibits covid-19 protease. The curcumin has potent antiviral activities against SARS-Coronavirus via inhibiting 3CL protease. It also boosts immune system and helps fight free radicals and prevents oxidative stress to cells and also binds to SARS-CoV-2 RBD of S-protein. The curcumin has potent antiviral effects, supports and protects respiratory system, and it also prevents cytokine storm. Curcumin may be a potential therapy for patients with severe viral infections, to help tackle the cytokine storm. It fights against several viruses such as Parainfluenza virus type 3 (PIV-3), Feline infectious peritonitis virus (FLPV), Vesicular stomatitis virus (VSV), Herpes simplex virus (HSV), Flock house virus (FHV), and Respiratory syncytial virus (RSV).
[00118] It also boosts immune health and has anti-viral and anti-bacterial and anti-inflammatory properties. It also prevents cytokine storm and has anti-cancer properties. Curcumin has been studied as a beneficial herb in cancer treatment and contributes to the death of cancerous cells, reduces angiogenesis (growth of new blood vessels in tumors), and also reduce metastasis (spread of cancer). In one embodiment, 95% Curcumin is extracted from, but not limited to, turmeric. Curcumin has potent antioxidant and anti-inflammatory effects, alleviating symptoms of ME/CFS, as well as being extremely potent in inhibiting Epstein-Barr virus activity.
100119] In one embodiment, the benefits of consuming 150 mg of olive leaf extract (with oleuropein + hydroxytyrosol) include, but not limited to, has antimicrobial activities and acts as an immunomodulator. It also protects the respiratory tract, increases interferon production in T NK Cells, stimulates phagocytosis, and enhances innate immunity. It also shortens symptoms of common cold, inhibits viral replication in respiratory tract, and acts as a cardioprotective by increasing nitric oxide. It also has anti-cancer properties and also supports respiratory system. Oleuropein and derivatives such as elenolic acid have been effective in vitro and animal studies against many microorganisms such as retroviruses, influenza, parainfluenza 3 in animal models, and bacteria. Plus has potent antioxidant and anti-inflammatory effects, illustrated by its very high ORAC score (a measure of anti-oxidant activity), alleviating symptoms of ME/CFS, as well as being effective in inhibiting Epstein-Barr virus activity.
100120] In one embodiment, the benefits of consuming 200 mg of Lions mane mushroom (with polyaccharides) include, but not limited to, acts as an immunomodulator and immunostimulatory. It also improves immune system function and has anti-microbial properties. Polysaccharides most important as immune stimulator, particularly in the intestinal tract for innate immunity. It is rich in active constituents of diterpenoid compounds, steroids, polysaccharides and other functional ingredients.
100121] In one embodiment, the benefits of consuming 250 mg of 50% Chlorogenic Acid, which could be extracted from the green coffee beans include, but not limited to, boosts the immune system, prevents fatigue, controls weight and obesity, and also has anti-viral and antibacterial activities. It acts as hepatoprotective, cardioprotective anti-inflammatory and neuroprotective. It also protects from respiratory viruses, promotes immune cell activation & proliferation, enhances immune cell surveillance, and also enhances immune cell killing capabilities. It may help treats influenza and alleviates lung inflammation. Chlorogenic Compounds from coffee beans exert activity against respiratory viruses. It could change gene expression and that the responsive genes involved in immune pathways had been significantly upregulated. Chlorogenic acid is an important and biologically active dietary polyphenol, playing several important and therapeutic roles such as antioxidant activity, antibacterial, hepatoprotective, cardioprotective, anti-inflammatory, antipyretic, neuroprotective, anti-obesity, antiviral, antimicrobial, anti-hypertension, free radicals scavenger and a central nervous system (CNS) stimul ator.
1001221 In one embodiment, the benefits of consuming 15 mg of elemental zinc from Zinc Picolinate /Oxide /Gluconate/ Citrate include, but not limited to, protects against respiratory infection and common cold, decreases incidence infection in elderly, and also inhibits coronavirus replication in Vitro. It stops RDRP replication of coronavirus in humans. It shows deficiency compromises immune health, inhibits viral replication and spread, developments and functions innate immunity, growths, developments and function of lymphocytes. It also reduces other infections Diarrhoea & UTI and also reduces incidence & duration resp tract infections and pneumonia.
100123] Zinc Picolinate/Oxide/Gluconate/Citrate has anti-cancer properties and also stabilizes and repairs DNA, and also prevents and treats oesophageal cancer. It promotes stem cell proliferation and differentiation into neurons, enhances stem cell thearapy for liver fibrosis, and also enhances cellular energy. The role of zinc in cancer has received increasing attention as a link between zinc deficiency and cancer has now been established in human studies and it is an essential element required for cell division, migration, and proliferation. Deficiency is linked to NIE/CFS, and administration increases antioxidant status, decreases oxidative stress thus treats symptoms of the disease.
1001241 In one embodiment, the benefits of consuming 15 mg of Piperine include, but not limited to, acts as an immunomodulator and also has anti-cancer properties. Piperine has been reported to inhibit the proliferation and survival of many types of cancer cells. It also has anti-viral and anti-inflammatory properties. It also prevents oxidative stress, thereby enhancing health and also ability to fight inflammation, improves cognitive and neurological health and brain function, as well as protect from the neurodegenerative disease, improves blood sugar metabolism and combat diabetes and also regulates cholesterol, inhibits proliferation and survival of many types of cancer cells, and also increases the absorption of essential nutrients and plant compounds, thereby boosting nutrient absorption and gut health. In one embodiment, the Piperine is extracted from black pepper.
1001251 In one embodiment, the benefits of consuming 5000 mg of D-ribose include, but not limited to, binds to various nucleic acids that allows these nucleic acids to act as energy intermediates (NADH, FADH, and ATP) or to form the structural basis of DNA and RNA. D-Ribose, a critical building block for nucleotides, plays an important role in energy metabolism, transcription, translation, and second messenger systems. It promotes immune cell differentiation and function, essential for mitochondrial function, and also enhances mitochondrial function. D-Ribose prevents / treats fibromyalgia and PFVS/MiE/CFS via reversing mitochondrial dysfunction, imparied cellular metabolism and enhancing ATP synthesis. It also enhances ATP recovery and reduces cellular injury and also prevents/treats chronic fatigue syndrome and fibromyalgia.
[00126] In one embodiment, the benefits of consuming 100 mg of Shilajit include, but not limited to, stimulates innate immune response, stimulates humoral and cellular immune response. It acts as an immunomodulator and has anti-viral and anti-cancer properties and also promotes cancer therapies and treatments. Shilajit has anti-cancer properties and also reduces anti-cancer drug side effects via antioxidant and by reducing inflammation. Shilajit can prevent / treat CFS/ ME via modulation of the hypothalamic pituitary adrenal (HPA) axis and preservation of mitochondiral function and integrity. Shilajit is a potent rejuvenator and having adaptogenic action. It also induces cancer cell apoptosis and inhibits proliferation, stimulates mesenchymal stem cell differentiation, and also treats osteoporosis and chronic fatigue syndrome by altering mitochondrial bioenergetics. It has anti-inflammatory properties and also prevents chronic inflammatory diseases and reduces muscle fatigue. In one embodiment, the shilajit includes fulvic acid and humic acid.
[00127] In one embodiment, the benefits of consuming 150 mg of Adenosine disodium triphosphate include, but not limited to, helps mitochondrial production of ATP (energy).
[00128] In one embodiment, the benefits of consuming 100 mg of L-carnosine include, but not limited to, enhances immune system response, acts as an immunoregulatory and promotes tissue repair, and also protects from immune dysfunction. It has anti-cancer properties and inhibits human gastric cancer by altering mitochondrial bioenergetics. L-carnosine alters mitochondrial bioenergetics, stimulates hemopoietic stem cells, and also prevents and treats chronic fatigue syndrome via scavenging free radicals in nervous tissue It acts as a neuroprotective against neurodegeneration [00129] Although a single embodiment of the invention has been described in the above detailed description, it will be understood that the invention is not limited to the embodiment developed herein, but is capable of numerous rearrangements, modifications, substitutions of parts and elements without departing from the spirit and scope of the invention.
[00130] The foregoing description comprises illustrative embodiments of the present invention. Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only, and that various other alternatives, adaptations, and modifications may be made within the scope of the present invention. Merely listing or numbering the steps of a method in a certain order does not constitute any limitation on the order of the steps of that method. Many modifications and other embodiments of the invention will come to mind to one skilled in the art to which this invention pertains having the benefit of the teachings presented in the foregoing descriptions. Although specific terms may be employed herein, they are used only in generic and descriptive sense and not for purposes of limitation. Accordingly, the present invention is not limited to the specific embodiments illustrated herein.
Claims (69)
- CLAIMSWhat is claimed is 1 A chemo-preventative and cytotoxic formulation for treating coronavirus and other infections, cancer, PVFS/ME/CFS, fibromyalgia, improving immune, mitochondrial, stem cell and brain function, and reversing epigenetic aging, in an individual, comprising: Ni cotin ami de Mononucl eoti de (NMN), Ni cotin am i de Adenine Dinucleotide (NAD), Pyrroquinoline Quinone (PQQ), Coenzyme Q10 (C0Q10), Piperine (black pepper extract), vitamin B7 (Biotin), vitamin B9, and vitamin B12.
- 2 The formulation of claim 1, further comprises Vitamin B1
- 3. The formulation of claim 2, wherein the composition further comprises Vitamin BI in the amount of about 10 mg to 300 mg.
- 4. The formulation of claim 2, wherein the composition further comprises Vitamin B I in the amount of about 100 mg.
- 5. The formulation of claim 2, wherein the vitamin B1 is selected from at least any one of; Benfotiamine, Thiamine and Sulbutiamine.
- 6. The formulation of claim 1, further comprises Vitamin B5.
- 7. The formulation of claim 6, wherein the composition further comprises Vitamin B5 in the amount from about 25 mg to 350 mg.
- 8. The formulation of claim 6, wherein the composition further comprises Vitamin B5 in the amount of about 100 mg.
- 9. The formulation of claim 6, wherein the vitamin B5 is selected from at least any one of Pantethine, Pantothenic Acid, Pantothenol (Panthenol), Dexpanthenol and Calcium Pantothenate.
- 10. The formulation of claim 1, further comprises Vitamin B6.
- 11. The formulation of claim 10, wherein the composition further comprises Vitamin B6 in the amount from about 25 mg to 350 mg.
- 12. The formulation of claim 10, wherein the composition further comprises Vitamin B6 in the amount of about 100 mg.
- 13 The formulation of claim 10, wherein the vitamin B6 is selected from at least any one of, Pyridoxine, Pyridoxal, Pyridoxine 5'-phosphate (P5P) and Pyridoxal 5'-phosphate (PLP).
- 14. The formulation of claim 1, further comprises a methyl source, wherein the methyl source is selected from at least any one of, Betaine HC1, Betaine Anhydrous, Trimethylglcyine (TMG), Betaine Nitrate or Dimethylglycine (DMG).
- 15. The formulation of claim 14, wherein the composition further comprises methyl source in the amount from about 25 mg to 250 mg.
- 16. The formulation of claim 14, wherein the composition further comprises methyl source in the amount of about 100 mg.
- 17. The formulation of claim 1, further comprises choline and magnesium sources, and also flavourings and sweeteners.
- 18. The formulation of claim 17, wherein the choline source is selected from at least any one of, Alpha Glycerol Phosphoryl Choline (Alpha GPC), CDP Citicoline, Phosphatidyl Choline or Choline Bitartrate.
- 19. The formulation of claim 17, wherein the magnesium source is selected from at least any one of, Magnesium L-Threonate, Magnesium Orotate, Magnesium Citrate, Magnesium Taurate, Magnesium Bisglycinate, Magnesium Aspartate or Magnesium Lactate
- 20. The formulation of claim 17, wherein the composition further comprises the choline and magnesium sources in the amount ranges from about 100 mg to 1000 mg.
- 21. The formulation of claim 17, wherein the composition further comprises choline and magnesium sources in the amount of about 500 mg.
- 22. The formulation of claim 1, wherein the vitamin B9 is selected from at least any one of Folic Acid, L-5-Methyl tetrahydrofolate-Ca (calcium & non calcium salt of MethylFolate) and (6S)-5-methyltetrahydrofolate (glucosamine salt)
- 23 The formulation of claim 1, wherein the vitamin B12 is selected from at least any one of, Methylcobalamin, Adenocobalamin, Hydroxocobalamin, and Cyanocobalamin
- 24. The formulation of claim 1, is provided in at least any one or more forms include capsules, tablets, liquid, liposomal, micelle, phospholipid or topical form, softgels, drinks, powder, medical food, intravenous and an oral composition.The formulation of claim 1, wherein the composition comprises: nicotinamide mononucleotide (NMN) in the amount from about 100 mg to 1000 mg taken into four equal doses; nicotinamide adenine dinucleotide (MAD) in the amount from about 100 mg to 1000 mg; pyrroquinoline quinone (PQQ) in the amount from about 5 mg to 50 mg; coenzyme Q10 (CoQ10) in the amount from about 50 mg to 500 mg; piperine in the amount ranges from about 5 mg to 50 mg; vitamin B7 (Biotin) in the amount from about 0.25 mg to 5 mg, vitamin B9 (L-Methyl tetrahydrofolate-Ca) in the amount from about 0.25 mg to 5 mg, and vitamin B12 (Methylcobalamin) in the amount from about 0.
- 25 mg to 5 mg.
- 26. The formulation of claim 1, wherein the composition comprises: nicotinamide Mononucleotide (NMN) in the amount of about 750 mg; nicotinamide Adenine Dinucleotide (MAD) in the amount of about 250 mg; pyrroquinoline Quinone (PQQ) in the amount of about 20 mg; coenzyme Q10 (C0Q10) in the amount of about 200 mg; piperine in the amount of about 15 mg; vitamin B7 in the amount of about 1 mg, vitamin B9 in the amount of about 1 mg, and vitamin B12 in the amount of about 1 mg.
- 27. A chemo-preventative and cytotoxic formulation for treating coronavirus and other infections, cancer, PVESTME/CFS, fibromyalgia, improving immune, mitochondrial, stem cell and brain function, and reversing epigenetic aging, in an individual, comprising: Resveratol, Pterostilbene, Quercetin, Baikal Skullcap, L-Theanine, Curcuminoids (Turmeric Extract), Lion's Mane Mushrooms, vitamin B1, vitamin B2, vitamin B5, vitamin B6, Piperine and Zinc Complex.
- 28 The formulation of claim 27, wherein the composition comprises Resveratrol in the amount from about 100 mg to 1000 mg, Pterostilbene in the amount from about 100 to 750 mg; Quercetin in the amount from about 100 mg to 750 mg; Baikal Skullcap in the amount from about 50 mg to 500 mg; L-Theanine in the amount from about 50 mg to 500 mg; Curcuminoids (Turmeric Extract) in the amount from about 50 mg to 500 mg; Lion's Mane Mushrooms in the amount from about 100 mg to 1000 mg; vitamin B1 in the amount from about 20 mg to 250 mg; vitamin B2 in the amount from about 25 mg to 350 mg; vitamin B5 in the amount from about 50 mg to 500 mg, vitamin B6 in the amount from about 25 mg to 350 mg, Piperine in the amount from about 5 mg to 50 mg, and Zinc complex in the amount from about 5 mg to 50 mg elemental zinc.
- 29. The formulation of claim 27, further comprises D-ribose, and methyl source.
- 30. The formulation of claim 29, wherein the composition comprises D-Ribose in the amount from about 1 g to 10 g and methyl source in the amount from about 250 mg to 2500 mg.
- 31. The formulation of claim 29, wherein the composition further comprises D-Ribose in the amount of about 5000 mg and the methyl source in the amount of about 1000 mg.
- 32. The formulation of claim 27, wherein the zinc complex is selected from at least any one of Zinc Picolinate, Zinc Citrate, Zinc Gluconate, and Zinc Oxide.
- 33 The formulation of claim 29, wherein the methyl source is selected from at least any one of Betaine HC1, Betaine Anhydrous, Trimethylglcyine (TMG), Betaine Nitrate or Dimethylglycine (DNIG).
- 34. The formulation of claim 27, further comprises Taurine and Creatine.
- 35. The formulation of claim 34, wherein the creatine source is selected from at least any one of Creatine Monohydrate, Creatine Hydrochloride, Creatine Citrate, Creatine Magnesium Chel ate and Creatine Nitrate.
- 36. The formulation of claim 34, wherein the composition comprises Taurine in the amount ranges from about 150 mg to 1500 mg and creatine in the amount ranges from about 250 mg to 2500 mg.
- 37. The formulation of claim 34, wherein the composition further comprises Taurine in the amount of about 500 mg and creatine in the amount of about 1000 mg.
- 38. The formulation of claim 27, wherein the composition is provided in at least any one or more forms include capsules, tablets, liquid, liposomal, micelle, phospholipid or topical form, soft gels, drinks, powder, medical food, intravenous and an oral composition.
- 39. The formulation of claim 27, wherein the composition comprises Resveratrol in the amount of about 300 mg; Pterostilbene in the amount of about 200 mg; Quercetin in the amount of about 250 mg; Baikal Skullcap in the amount of about 200 mg; L-Theanine in the amount of about 250 mg; Curcuminoids (Turmeric Extract) in the amount of about 200 mg; Lion's Mane Mushrooms in the amount of about 200 mg; vitamin B1 in the amount of about 100 mg; vitamin B2 in the amount of about 150 mg; vitamin B5 in the amount of about 250 mg; vitamin B6 in the amount of about 100 mg, Piperine in the amount of about 15 mg, and Zinc complex in the amount of about 15 mg elemental zinc
- 40. A chemo-preventative and cytotoxic formulation for treating coronavirus and other infections, cancer, PVFS/ME/CFS, fibromyalgia, improving immune, mitochondrial, stem cell and brain function, and reversing epigenetic aging, in an individual, comprising: Alpha Lipoic Acid (ALA), Acetyl-L-Carnitine (ALCAR), N-Acetyl Cysteine (NAC), Ginkgo Biloba, Beta Glucans, Epigallocatechin 3-Gallate (EGCG), Green Tea Extract, Pomegranate Extract (incl. Ellagic Acid), Olive Leaf Extract (incl. Oleuropein and Hydroxytyrosol), Green Coffee Bean Extract (incl. Chlorogenic Acids), Theacrine and piperine.
- 41 The formulation of claim 40, wherein the composition further comprises Methylliberine in the amount from about 25 mg to 250mg
- 42. The formulation of claim 41, wherein the composition further comprises Nlethylliberine in the amount of about 100 mg.
- 43. The formulation of claim 40, wherein the composition further comprises Adenosine disodium triphosphate in the amount from about 100 mg to 1000 mg.
- 44. The formulation of claim 43, wherein the composition further comprises Adenosine disodium triphosphate in the amount of about 200 mg.
- 45. The formulation of claim 40, wherein the composition further comprises Shilajit (mineral pitch containing Humic & Fulvic Acids).
- 46. The formulation of claim 45, wherein the composition further comprises Shilajit (mineral pitch containing Humic & Fulvic Acids) in the amount from about 25 mg to 250mg.
- 47. The formulation of claim 45, wherein the composition further comprises Shilajit (mineral pitch containing Humic & Fulvic Acids) in the amount of about 100 mg.
- 48 The formulation of claim 40, wherein the composition comprises: Alpha Lipoic Acid (ALA) in the amount from about 50 mg to 500 mg; Acetyl-L-Carnitine (ALCAR) in the amount from about 50 mg to 500 mg; N-Acetyl Cysteine (NAC) in the amount from about 100 mg to 1000 mg; Beta Glucans in the amount from about 50 mg to 500 mg; EGCG in the amount from about about 50 mg to 500 mg; Green Tea Extract in the amount from about about 50 mg to 500 mg; Pomegranate Extract (incl. Ellagic Acid) in the amount from about 50 mg to 500 mg; Ginkgo Biloba in the amount from about 50 mg to 500 mg Olive Leaf Extract (incl. Oleurope n and Hydroxytyrosol) in the amount from about 50 mg to 500 mg, Green Coffee Extract (incl, Chlorogenic Acids) in the amount from about 50 mg to 500 mg; Theacrine in the amount from about 25 mg to 250 mg, and Piperine in the amount ranges from about 5 mg to 50 mg.
- 49. The formulation of claim 40, wherein the composition comprises: Alpha Lipoic Acid (ALA) in the amount of about 200 mg; Acetyl-L-Carnitine (ALCAR) in the amount of about 250 mg; N-Acetyl Cysteine (NAC) in the amount of about 300 mg; Beta Glucans in the amount of about 200 mg; EGCG in the amount of about 150 mg; Green Tea Extract in the amount of about 150 mg; Pomegranate Extract (incl. Ellagic Acid) in the amount of about 200 mg; Ginkgo Biloba in the amount of about 200 mg; Olive Leaf Extract (incl. Oleuropein and Hydroxytyrosol) in the amount of about 150 mg; Green Coffee Extract (incl. Chlorogenic Acids) in the amount of about 250 mg; Theacrine in the amount of about 100 mg, and Piperine in the amount of about 15 mg.
- 50. The formulation of claim 40, further comprises Vitamin BL
- 51. The formulation of claim 50, wherein the composition further comprises Vitamin B1 in the amount from about 25 mg to 250 mg.
- 52. The formulation of claim 50, wherein the composition further comprises Vitamin B1 in the amount of about 100 mg.
- 53 The formulation of claim 50, wherein the vitamin B1 is selected from at least any one of Benfotiamine, Thiamine and Sulbutiamine.
- 54. The formulation of claim 40, further comprises Vitamin B5.
- 55. The formulation of claim 54, wherein the composition further comprises Vitamin B5 in the amount from about 50 mg to 500 mg.
- 56. The formulation of claim 54, wherein the composition further comprises Vitamin B5 in the amount of about 200 mg.
- 57 The formulation of claim 54, wherein the vitamin B5 is selected from at least any one of, Pantethine, Pantothenic Acid, Pantothenol (Panthenol), Dexpanthenol and Calcium Pantothenate,
- 58 The formulation of claim 40, further comprises Vitamin B6.
- 59. The formulation of claim 58, wherein the composition further comprises Vitamin B6 in the amount from about 25 mg to 350 mg.
- 60. The formulation of claim 58, wherein the composition further comprises Vitamin B6 in the amount of about 100 mg.
- 61. The formulation of claim 58, wherein the vitamin B6 is selected from at least any one of Pyridoxine, Pyridoxal, Pyridoxine 5'-phosphate (P5P) and Pyridoxal 5'-phosphate (PLP).
- 62. The formulation of claim 40, further comprises Vitamin B7 Biotin.
- 63. The formulation of claim 62, wherein the composition further comprises Vitamin B7 Biotin in the amount from about 0.1 mg to 5 mg.
- 64. The formulation of claim 62, wherein the composition further comprises Vitamin B7 Biotin in the amount of about I mg.
- The formulation of claim 40, further comprises Vitamin B2
- 66. The formulation of claim 65, wherein the composition further comprises Vitamin B2 in the amount from about 25 mg to 250 mg.
- 67. The formulation of claim 65, wherein the composition further comprises Vitamin B2 in the amount of about 200 mg.
- 68. The formulation of claim 40, wherein the Beta glucans is selected from at least any one of, Mushrooms, Oat, Barley or Yeast.
- 69 The formulation of claim 40, is provided in at least any one or more forms include capsules, tablets, liquid, lipisomal, micelle, phospholipid or topical form, soft gels, drinks, powder, medical food, intravenous and an oral composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2010600.1A GB2596849A (en) | 2020-07-10 | 2020-07-10 | Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2010600.1A GB2596849A (en) | 2020-07-10 | 2020-07-10 | Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual |
Publications (2)
Publication Number | Publication Date |
---|---|
GB202010600D0 GB202010600D0 (en) | 2020-08-26 |
GB2596849A true GB2596849A (en) | 2022-01-12 |
Family
ID=72139995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB2010600.1A Pending GB2596849A (en) | 2020-07-10 | 2020-07-10 | Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2596849A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022143710A1 (en) * | 2020-12-31 | 2022-07-07 | 南京舒鹏生物科技有限公司 | Use of pyrroloquinoline quinone, derivative and/or salt thereof as novel antiviral drug and pharmaceutical composition thereof |
NL2035081A (en) * | 2023-06-13 | 2023-07-11 | Eternal Grace Pte Ltd | Composition promoting absorption and utilization of nutrients and intervention factors |
WO2023217994A1 (en) * | 2022-05-12 | 2023-11-16 | Alzchem Trostberg Gmbh | Composition comprising creatine for use in the treatment of post viral fatigue syndrome |
EP4311549A1 (en) * | 2022-07-28 | 2024-01-31 | AlzChem Trostberg GmbH | Composition comprising creatine for use in the treatment of post viral fatigue syndrome |
WO2024089454A1 (en) * | 2022-10-28 | 2024-05-02 | Pharmanutra S.P.A. | Nutraceutical composition for use in the treatment of post covid-19 chronic fatigue / fatigue |
WO2024125113A1 (en) * | 2022-12-13 | 2024-06-20 | 泓博元生命科技(深圳)有限公司 | Composition for preventing and treating cytokine storm |
WO2024118756A3 (en) * | 2022-11-29 | 2024-07-11 | Accuri, Llc | Compositions for raising nad levels and methods and uses thereof |
WO2024201281A1 (en) * | 2023-03-28 | 2024-10-03 | Wonderfeel | Methods and compositions for treatment of pain |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113170889A (en) * | 2021-05-21 | 2021-07-27 | 卢静 | Compound anti-aging composition, compound anti-aging tablet, and preparation method and application thereof |
TW202313081A (en) * | 2021-06-07 | 2023-04-01 | 全球預防醫學生技股份有限公司 | Method and composition for preventing and treating covid-19 and long covid |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160030311A1 (en) * | 2014-07-30 | 2016-02-04 | Minerva Research Labs Ltd | Anti-aging antioxidant nutritional supplement for the improvement of the integumentary system |
CN106265730A (en) * | 2016-05-17 | 2017-01-04 | 深圳市太生源健康产业有限公司 | The pyrroloquinoline quinone (PQQ) application in the reverse effect to multi-drug resistance of the tumor |
CN109966427A (en) * | 2019-05-20 | 2019-07-05 | 北京震旦鼎泰健康管理有限公司 | A kind of fermentation living bacterial liquid and preparation method thereof treated tumour and improve immunity of organisms |
US20190350960A1 (en) * | 2017-01-04 | 2019-11-21 | President And Fellows Of Harvard College | Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same |
-
2020
- 2020-07-10 GB GB2010600.1A patent/GB2596849A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160030311A1 (en) * | 2014-07-30 | 2016-02-04 | Minerva Research Labs Ltd | Anti-aging antioxidant nutritional supplement for the improvement of the integumentary system |
CN106265730A (en) * | 2016-05-17 | 2017-01-04 | 深圳市太生源健康产业有限公司 | The pyrroloquinoline quinone (PQQ) application in the reverse effect to multi-drug resistance of the tumor |
US20190350960A1 (en) * | 2017-01-04 | 2019-11-21 | President And Fellows Of Harvard College | Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of same |
CN109966427A (en) * | 2019-05-20 | 2019-07-05 | 北京震旦鼎泰健康管理有限公司 | A kind of fermentation living bacterial liquid and preparation method thereof treated tumour and improve immunity of organisms |
Non-Patent Citations (2)
Title |
---|
Arthritis research & therapy, Vol. 11, No. 2, R49, 2009, Bang et. al., "Anti-inflammatory and antiarthritic effects of piperine in human interleukinsynoviocytes and in rat arthritis models". * |
Nature Scientific Reports, Vol. 10, No. 651, Wilk et. al., Extracellular NAD+ enhances PARP-dependent DNA repair capacity independently of CD73 activity, Available from: https://www.nature.com/articles/s41598-020-57506-9 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022143710A1 (en) * | 2020-12-31 | 2022-07-07 | 南京舒鹏生物科技有限公司 | Use of pyrroloquinoline quinone, derivative and/or salt thereof as novel antiviral drug and pharmaceutical composition thereof |
WO2023217994A1 (en) * | 2022-05-12 | 2023-11-16 | Alzchem Trostberg Gmbh | Composition comprising creatine for use in the treatment of post viral fatigue syndrome |
EP4311549A1 (en) * | 2022-07-28 | 2024-01-31 | AlzChem Trostberg GmbH | Composition comprising creatine for use in the treatment of post viral fatigue syndrome |
WO2024089454A1 (en) * | 2022-10-28 | 2024-05-02 | Pharmanutra S.P.A. | Nutraceutical composition for use in the treatment of post covid-19 chronic fatigue / fatigue |
WO2024118756A3 (en) * | 2022-11-29 | 2024-07-11 | Accuri, Llc | Compositions for raising nad levels and methods and uses thereof |
WO2024125113A1 (en) * | 2022-12-13 | 2024-06-20 | 泓博元生命科技(深圳)有限公司 | Composition for preventing and treating cytokine storm |
WO2024201281A1 (en) * | 2023-03-28 | 2024-10-03 | Wonderfeel | Methods and compositions for treatment of pain |
NL2035081A (en) * | 2023-06-13 | 2023-07-11 | Eternal Grace Pte Ltd | Composition promoting absorption and utilization of nutrients and intervention factors |
Also Published As
Publication number | Publication date |
---|---|
GB202010600D0 (en) | 2020-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2596849A (en) | Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual | |
US20070292493A1 (en) | Pharmaceutical composition and method for the transdermal delivery of calcium | |
US20130064803A1 (en) | BIO-REPLENISHMENT (BioRep) FOR COGNITIVE HEALTH | |
US20080102137A1 (en) | Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization | |
US10201553B1 (en) | Composition of natural products for improved brain functioning | |
US10842839B2 (en) | Natural formulation for treating hangover | |
ES2207287T3 (en) | USE OF CARNITINS AND RESVERATROL TO PRODUCE A COMPOSITION FOR THE PREVENTION OR THERAPEUTIC TREATMENT OF CEREBRAL DISORDERS PRODUCED BY THE AGING AND USE OF NEUROTOXIC PHARMACOS. | |
CN101248873A (en) | Drinking food product with sight protection function | |
WO2013108262A1 (en) | Synergistic combination for the treatment of diabetic neuropathy | |
EP3691621B1 (en) | Neupanex ®: neuroprotective, neuroregenerational,&neurogenesis supporting supplement combination | |
US9877939B2 (en) | Composition and methods for the production of S-adenosylmethionine within the body | |
US20170020834A1 (en) | Prophylactic use of neuroprotectants in sports-related traumatic brain injury | |
TW201713330A (en) | Composition for suppressing muscular fatty change | |
KR100711276B1 (en) | Utilization of phosphatidylserine in the treatment of attention deficit syndrome ADHS | |
GB2585619A (en) | A supplement | |
US10500182B2 (en) | Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache | |
RU2709500C1 (en) | Pharmaceutical composition for parenteral drip introduction | |
RU2707948C1 (en) | Pharmaceutical composition for parenteral drip introduction (versions) | |
US20200237812A1 (en) | Compound and Composition for Use in the Preventive and/or Curative Treatment of Diseases of the Central Nervous System Characterised by a Decline in Neuronal Plasticity, in Particular Characterised by a Decline in Synaptic Plasticity | |
WO2011041920A2 (en) | Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin b12 and vitamin b6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing | |
US11116246B2 (en) | Compositions of coenzyme Q10 and methods of use | |
US20230139125A1 (en) | Dietary supplement for improving brain performance | |
RU2709501C1 (en) | Pharmaceutical composition for parenteral drip introduction | |
KR20010021694A (en) | Nutritional composition for subjects under stress | |
FI3634396T3 (en) | Composition for improving efficacy of l-dopa treatment |